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Chapter 1
Introduction
The stimulus to embark on this thesis came from observation of the clinical challenges in effective cancer 
pain control, combined with the evidence for these challenges in the literature. Contrary to common 
beliefs, the difficulties in cancer pain management are not related to lack of understanding of pain 
mechanisms nor available treatments, rather the more common barriers are related to fear o f opioids. Most 
patients diagnosed with cancer will require opioid analgesics at some time during their disease, and many 
will eventually require strong opioids.' In industrialised countries, 30-80% of cancer patients receive 
insufficient pain therapy, although physicians could ensure at least moderate pain relief for most patients 
by following the World Health Organisation (WHO) guidelines for treatment of cancer pain.^'"
The required dose of opioids is often underestimated. Physicians are concerned about serious side effects 
such as respiratory depression and addiction, and it has been shown that patients and their relatives not only 
share their physicians’ concerns about addiction, but also are anxious about opioid efficacy during long­
term treatment. Such concerns may lead to reduced patient compliance.®
Opioid drugs hold a paradoxical position in modern society. On the one hand they are recognised as the 
keystone to successful pharmacological management of cancer pain of moderate to severe intensity^ and 
have an acknowledged role in the management of chronic non-malignant pain,® however on the other hand 
they are seen as drugs of addiction and abuse and have medical, legal or social consequences. There has 
been little contact between those who prescribe opioids for pain and those who deal with the consequences 
o f abuse.
There are barriers to the appropriate use of opioids as analgesics: a fundamental problem is lack of 
understanding o f commonly used terminology leading to misunderstandings, in relation to opioid 
analgesia^ and another problem is fear of addiction and tolerance to opioid analgesia in both prescribers,
patients and carers.'” These two problems are obviously linked in some cases. An important landmark 
study was carried out by Paice, Toy and Shott. This study examined the real factors associated with poor 
pain relief. Factors associated with higher pain intensity included the inpatient setting, the presence of 
metastatic disease, hesitancy in bothering the nurse, and concerns regarding tolerance and addiction. 
Although there was a strong relationship between concern about addiction and concern about tolerance, 
fear of tolerance appeared to have a greater effect on pain intensity scores than did fear of addiction.'” The 
clinical implications are that these areas need to be addressed; we need more information, a consensus on 
these areas in pain management and effective education.
Tolerance is present when there is a need to increase the dose of a drug that is taken at a regular interval in 
order to sustain its initial effects. Tolerance does not usually develop to all o f the drugs effects nor may it 
develop at a uniform rate with a specific drug. The precise mechanisms by which tolerance develop have 
not been completely defined. The multiplicity of opioid receptors and receptor subtypes (mu, delta, kappa 
and possibly others) and the limited knowledge of their coupling mechanisms underpin why cellular and 
biochemical changes underlying opioid tolerance and physical dependence remain poorly understood. 
Following chronic exposure to opioids, both down and up regulation of opioid receptors can occur, 
depending on the receptor type and/or the region examined. ' ' As these changes generally appear after the 
tolerance is installed, they are unlikely to be responsible for it. However, opioid tolerance seems to be 
associated with some uncoupling (probably functional rather than physical) of the opioid receptors from G 
proteins normally associated with them, therefore resulting in a loss of the capacity of these proteins to 
exchange GDP for GTP.'^
We know that clinically relevant pharmacological tolerance is not an issue in cancer pain management in 
the majority of cases. This has however not been carefully examined.
Physical dependence occurs as a consequence of exposure to a drug, resulting in physiological changes 
necessitating the continued presence of the drug to maintain normal function.'^ An increase in adenylate
cyclase activity, and therefore of cyclic AMP levels and certain protein kinase activities, have been claimed 
to be responsible for physical dependence in some cell types.'® We know physical dependence may occur 
with the use of opioids as analgesics, however we do not know the prevalence.
Psychological dependence, or addiction which is a sociological term that has come to mean the presence of 
compulsive drug-seeking behaviour is usually accompanied by physical dependence and tolerance. The 
mechanisms of psychological dependence are complex and not simply associated with opioid use.''*’ '® 
However, physical dependence is not always accompanied by psychological dependence and it is this 
common misunderstanding that fuels fear o f appropriate opioid use.
It is evident that these phenomena of tolerance, physical and psychological dependence are complex, 
however clarity of use of these terms is important, currently it is not optimal and this is confounded by a 
lack of systematic evaluation of these phenomena in pain patients. These are important barriers to good 
patient care.'”
The aims of this thesis are to clarify beliefs in clinical practice about opioid dependence, both physical and 
psychological and opioid tolerance. The studies chosen as a means to this clarification are clearly clinical 
and 1 will divide them into the areas they cover.
The first study has the hypothesis: Patients with pain and who use opioid analgesia do not become 
addicted to opioids. To demonstrate this, 3 groups of patients had their patterns of opioid use compared: 
chronic cancer pain patients, chronic non-malignant pain patients and drug addicts.
The second study has the hypothesis: Patients with chronic cancer pain and with chronic non-malignant 
pain can use stable opioid doses over many months, even years, without needing to increase the opioid 
dose to maintain the same level o f analgesia. This study addresses the question of clinically relevant 
pharmacological tolerance and was a follow-on study from the first study.
The third study addresses the question of physical dependence on strong opioids which clinically results in 
a physical opioid withdrawal syndrome on sudden discontinuation of opioids. The hypothesis is: Patients 
receiving a continuous intravenous infusion of diamorphine to treat painful mucositis post bone marrow 
transplant, can discontinue the diamorphine infusion abruptly when pain resolves, without developing a 
physical opioid withdrawal syndrome.
Clearly these three studies are linked: they address the three key areas of fear when using opioids; 
psychological dependence, clinically relevant pharmacological tolerance and physical dependence.
In addition to these key fundamental areas I examined important related areas. The first was the 
development of selective tolerance to the opioid side effect of constipation, and the relationship between 
opioid dose and constipation. The hypotheses were: (i) opioid dose is related to the degree of constipation 
and (ii) patients on stable opioid doses become tolerant to the constipation side-effect.
The final thread of the thesis is the complex question of whether morphine tolerance can be an important 
mechanism at spinal cord level, in patients with the clinical phenomena correlating to central wind-up. 
This specific mechanism of tolerance does occur in chronic pain and renders certain pains relatively 
unresponsive or completely unresponsive to morphine. This Is clearly distinct from the general 
phenomenon of tolerance which is not clinically relevant in chronic pain management. The phenomenon 
of central wind-up which we know is mediated via the N-methyl-D-aspartate (NMDA) receptor is thought 
to be linked to morphine tolerance possibly via a nitric oxide synthetase mechanism. The result is pain 
with the specific features o f allodynia, hyperalgesia and hyperpathia. This pain is classically morphine 
poorly-responsive or unresponsive. Animal studies have shown that NMDA antagonists such as ketamine 
can reverse this state.”
The hypothesis for the final study is: Patients on morphine but with clinical phenomena of central wind­
up can have improved analgesia with the introduction of ketamine to their analgesic regimen.
Together, examination of these hypotheses is o f direct clinical significance in cancer pain management, 
given that all the literature points to fear of addition and tolerance as the greatest barriers to cancer pain 
control on a world wide basis.
I had the great fortune to be guided by Professor Geoffrey Hanks (GH) in this thesis. He steered a group 
of experts in the fields of cancer pain (GH), addiction medicine (Professor Ghodse, St George’s Hospital, 
London) and chronic non-malignant pain (Dr Amanda C de Williams, St Thomas’s Hospital, London). I 
also had advice from Professor Michael Gossop, Addiction Medicine, Maudsley Hospital, London.
The largest part of the work for this thesis was carried out in St Thomas’ Hospital (Oncology and Chronic 
Pain units) and in St George’s Hospital (Addiction unit) London, and in the Bone Marrow Transplant Unit, 
Bristol.
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Chapter 2
Definitions, Clinical Relevance And Misconceptions 
Tolerance, physical dependence and addiction:
Health care professionals, patients and families have exaggerated concerns about opioids and their potential side 
effects, in particular tolerance, physical dependence and addiction. Therefore it is critically important to understand 
the meaning of these terms and their clinical relevance to the management of cancer pain.
Tolerance
Definition:
Tolerance is a physiological state characterised by a decrease in the effects of a drug (e.g., analgesia, nausea or 
sedation) with chronic administration.
Clinical relevance:
It is important to distinguish between tolerance to analgesia and tolerance to side effects.
(1) Tolerance to analgesia.
Patients with unchanging pain can have a consistent level of pain relief from the same dose of opioids 
over time.' ® The need for higher doses of opioids is typically due to worsening pain and disease 
progression, rather than tolerance.
Tolerance to opioid side effects.
Tolerance usually develops to many of the side effects of opioids (sedation, nausea, itch) in a few days. 
The relationship between constipation and tolerance is very complex.
Misconceptions:
• To some, the need to increase the dose in response to the patient’s report of pain is misinterpreted as a sign that 
tolerance may be developing. Unfortunately, this sometimes leads the physician to reduce the dose in a mistaken 
attempt to avoid or delay the development of tolerance. The appropriate response is to reassess the pain and 
increase the dose as indicated to relieve pain.
e Sometimes, to prevent the development o f analgesic tolerance, opioids are administered at intervals which are too
far apart to maintain continuous pain relief. This practice is inappropriate because it subjects patients to needless 
cycles of pain and pain relief.
• Often, health care professionals and patients are concerned about using opioids from the 3'^ '' step o f the WHO 
ladder, such as morphine, because of the mistaken belief that the medication will lose its analgesic effect; they 
want to save it until the pain is really severe.'’ This concern about analgesic tolerance is unfounded and can lead to 
inadequate pain management.
• Some health care workers and patients believe that using morphine for pain relief will suppress respiration and 
possibly cause death. In fact, clinically significant respiratory depression and sedation are very rare in cancer 
patients. This is because tolerance to the sedative effects o f morphine develops rapidly, and because pain reverses 
morphine’s depressant effects.®
Physical dependence 
Definition:
Physical dependence is the physiological adaptation of the body to the presence of an opioid. It is defined by the 
development of withdrawal symptoms when opioids are discontinued, when the dose is reduced abruptly or when an 
antagonist (e.g., naloxone) or an agonist-antagonist (e.g., pentazocine) is administered.”
Clinical relevance
Physical dependence is a normal and expected response to continuous opioid therapy. Physical dependence may occur 
within a few days of dosing with opioids, although it varies among patients. Physical dependence (indicated by 
withdrawal symptoms) does not mean that the patient is addicted.”
Health care workers should advise patients to take their pain medication as directed, and that withdrawal symptoms 
may occur if they reduce their dose or stop taking the medication.’ Symptoms of withdrawal may include agitation, 
insomnia, diarrhoea, sweating, and rapid heart beat. If the source of pain is successfully treated or removed, physical 
dependence is easily treated by gradually decreasing the opioid dose.
The development of physical dependence should not limit analgesic therapy. Antagonists and agonist-antagonists in 
the patient who is physically dependent should be strictly avoided because their use will neutralize the analgesic effect 
and cause a withdrawal syndrome. The prevalence o f physical dependence is not known.
Misconceptions
• Physical dependence is frequently equated mistakenly with addiction. It is incorrect to use the term ‘physical 
dependence’ (a physiological state) to describe addiction (a dysfunctional psychological and behavioral 
syndrome).'
• Patients who express concern about physical dependence should be given correct information and reassured.
Addiction
Definition:
While tolerance and physical dependence are physical changes in the body, addiction is defined by aberrant changes In 
behaviour. Addiction is compulsive use of drugs for non-medical reasons; it is characterized by a craving for mood 
altering drug effects, not pain relief.® Addiction means dysfunctional behaviour, in sharp contrast to the improved 
function and quality of life that result from pain relief. Aberrant behaviours which indicate addiction may include: 
denial of drug use; lying; forgeiy of prescriptions; theft or drugs from other patients or family members; selling and 
buying drugs on the street; using prescribed drugs to get “high”.®
Clinical relevance:
Addiction is extremely rare in cancer patients who use opioids for pain. Biochemical, social and psychological factors 
are more important in the development o f addiction. Opioids should not be withheld for fear that a patient will become 
addicted. If a pain patient requests a strong analgesic, it is likely that the patient has inadequate pain control. 
Misconceptions
« People who fear addiction, yet desire pain relief sometimes think “So what if I get addicted, I am going to die 
anyway.”
• Patients and family members who express concern about addiction should be given correct information and 
reassured,
Pseudo-Addiction
Definition
Pseudo-addiction describes what happens when healthcare workers perceive as addictive behaviour a pain patient’s 
requests for more or stronger pain medications. In fact, the patient’s behaviour may be a response to inadequate pain 
management.” Pseudo-addictive behaviour is pain-relief seeking behaviour. Pseudo-addiction is an iatrogenic 
phenomenon, e.g. it is when problems result from the treatment efforts of health professionals.
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Clinical relevance
Pseudo-addictive behavior may occur when analgesics are prescribed in inadequate doses or at dosing intervals that are 
longer than the duration of action of the drug.’ Pseudo-addictive behaviors are more likely to occur in patient care 
settings where health care professionals are inadequately trained in pain management and the rational use of opioids. 
The appropriate clinical response to pseudo-addictive behaviors is to reassess the patient’s pain and to treat the pain 
adequately.
Other terminology in this thesis
In addition to dependence and tolerance terminology clarification of the following three terms used to describe 
elements of neuropathic pain is necessary for complete understanding of this thesis.
Allodynia: pain to a stimulus which is usually non-painful e.g. light touch.
Hyperalgesia: increased pain to a painful stimulus.
H yperpathia: prolonged duration of pain.
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Chapter 3
Do patients with pain become addicted to morphine?
Derivatives of the opium poppy have been successfully used for millennia for the desirable effect of 
pain relief and when used for the euphorigenic effects (which are not universal), they are generally 
being used for recreational purposes. While benefits have been universally recognised, the capacity of 
opioids to cause suffering has been equally appreciated through the course of history. ' The status of 
opioids in medical practice has gone through cycles o f favour to disrepute.  ^ Medical practice with 
respect to the use of opioids for the treatment of pain has been heavily influenced by societal 
perceptions of addiction problems or psychological dependence and by laws controlling the use of 
opioids. Despite improving education the evidence exists to demonstrate that fear o f producing 
addiction to opioids is foremost in the minds of most physicians when asked to provide medication for 
pain relief. This fear often interferes with their ability to provide adequate analgesia.®
One study demonstrates that those physicians who thought the probability of addiction was high after 
prescribing pethidine (meperidine) for ten days to a patient in pain were more likely to give lower 
initial doses, as well as to be less likely to respond to the need for increased medication with recurrent 
pain even if pain was due to terminal malignancy." A second study of 100 patients with malignant pain 
found 60 per cent to be prescribed doses of pethidine o f 50 mg or less, with 11 per cent having to wait 
for five or more hours before another dose with all prescriptions written for ‘PRN’ administration. ®
In fact, the risk of initiating an addiction when opioids are prescribed appropriately for relief of pain is 
very small. Historical references attribute physicians as initiating dependence on opioids. Two early 
surveys (in 1925 and 1939) o f addicts undergoing treatment reported that 9% and 4% respectively 
began their addiction with a medical prescription of an opioid drug for a painful disorder. ” In 1954, a 
report noted that 27% of white male addicts and 1.2% of black male addicts began abuse as medical 
patients treated for pain. Surveys of addicted populations are clearly subject to bias and a different
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view has emerged from more recent data on medical patients who were assessed for the development 
of addiction after receiving opioids for the treatment of pain.
Another survey reviewing addiction among a population of black heroin addicts found less than 2 
percent to attribute their addictions to prescription of an opioid for medical reasons. ® Perhaps the 
largest survey of iatrogenic opioid dependence was done as part of the Boston Collaborative Drug 
Surveillance Program.” This program monitors all drug exposures in several hospitals, with 
information being extracted from clinical records and by interviews with patients and physicians. Of 
over 11,000 hospitalised medical patients who had opioids administered during their hospital stay, only 
four were reported to have become addicted.
Abnormal drug-seeking behaviour was not seen when long-term opioids were used for postherpetic 
neuralgia, phantom limb pain," chronic spinal pain, and pain of mixed but well defined origin. "  
Taub described 313 personally treated patients with intractable pain who were maintained on opioid 
analgesics for up to 6 years. Only 13 patients presented serious management problems, and each of 
them had a history of substance abuse (opioids or alcohol).'" Portenoy also identified this risk factor in 
his study of 38 patients treated with opioids for non-malignant pain; the two patients who required 
escalating doses of opioids each had a history of drug abuse.'®
At the other end of the spectrum, Maruta found that 65 per cent of 144 consecutive patients referred for 
chronic non-malignant pain management were abusing or ‘dependent on’ weak and strong opioid drugs 
and had a strong family history of alcohol abuse.'” These data seem contradictory, however many 
factors, including basic definitions of dependence, have been a problem in such studies to date.
Addiction has been shown to be more complex than just the result o f repeated exposure to a drug.
There was high prevalence of opioid addiction among US soldiers in Vietnam; however, surveys of 
returning veterans demonstrated that a large proportion of those who abused heroin stopped this 
activity abruptly on return to a normal life in the U.S. and that the relapse rate was low. ”  In sharp
14
contrast, a group of drug addicts who underwent a 6 month in-patient treatment programme under the 
Narcotic Addict Rehabilitation Act were re-addicted within 6 months of their release.
These observational studies and case series give an indication o f a spectrum of response to opioid 
analgesia, ranging from appropriate use to inappropriate drug-seeking behaviour.
However, misapprehension fuelled by limited good quality data continues to fuel underprescription of 
opioids. A recent analysis o f publications pertaining to drug or alcohol dependence in chronic pain 
patients found less than one-tenth of these publications used acceptable criteria for drug misuse or even 
gave percentages of dependence problems. Physician opiophobia is an area of medicine which needs 
to be addressed, however a fundamental requirement is the need for meaningful, good quality data.'®
Addiction has been defined as ‘a behavioural pattern of drug use, characterised by overwhelming 
involvement with the use of a drug (compulsive use), the securing of its supply, and the high tendency 
to relapse after withdrawal’. '” A task force o f the Panels on Alcoholism and Drug Abuse of the 
American Medical Association (AMA) Council on Scientific Affairs formulated the following 
definitions;
Addiction: ‘a chronic disorder characterised by the compulsive use of a substance resulting in physical, 
psychological or social harm to the user and continued use despite that harm.” ”
Addict : ‘ a person who is physically dependent on one or more psychoactive substances, whose long­
term use has produced tolerance, who has lost control over his intake, and would manifest withdrawal 
phenomenon if discontinuance were to occur,’ Although this includes the terms physical dependence 
and tolerance, these exist along with loss o f personal control in the addict. In the patient with pain, 
physical dependence and tolerance may occur but without loss of personal control.
It is obvious that these definitions of addiction or psychological dependence have limited value in the 
patient with either chronic malignant or chronic non-malignant pain and a more exploratory approach
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is required to extract any evidence of psychological dependence in these groups. It is entirely 
reasonable that if opioids control pain for our patients they then will continue to request them. In 
addition, if inappropriate dosing is prescribed, the patient will reasonably request an increase in dose to 
control pain. This sensible therapeutic use is obviously not addiction.
We ‘know’ that addiction generally is not a problem in patients receiving opioids for pain. However, 
we do not know why, and we are unable to explain it on the basis of existing data. This observational 
study was planned with the intention of making a preliminary attempt to characterise, compare and 
contrast three groups of patients, to see whether there were any essential demographic differences, 
psychological differences and differences in the way the drugs were used. The three groups were: 
patients with cancer pain, patients with chronic non-malignant pain and drug addicts on a methadone 
maintenance programme.
The hypothesis for this study is: patients with pain and using opioid analgesia do not show patterns of 
opioid use similar to drug addicts.
Aim
To begin to investigate the question of addiction to opioids in patients with pain we studied three 
groups: cancer patients taking opioids for pain, patients with chronic non-malignant pain taking regular 
opioids and drug addicts on a methadone maintenance programme. Medical and personal data, mood, 
and patterns of drug use were compared in the three groups. In addition patients were rated using 
validated scales for opioid addiction (S.D.S) and for opioid withdrawal (S.O.W.S)
Methods
Ethical approval for the study was obtained from St Thomas’ Hospital and all included gave written |
I
informed consent. Thirty patients in each of the 3 patient groups were enrolled in the study. I
Consecutive patients with cancer pain on strong opioids and a prognosis o f at least 3 months referred to |
16
the palliative care team of a large London teaching hospital with an oncology unit were considered for 
inclusion in the study. All patients approached agreed to take part in the study. Many of these patients 
referred to the palliative care team for pain control, had difficult pain syndromes and were using large 
quantities of opioids. The oral morphine equivalent doses in this study group were unusually high, at
the upper end of the usual range, however some of the patients in this study had severe neuropathic
pain, shown to require very high opioid doses.
The patients with chronic non-malignant pain included in the study had been referred to a tertiary 
Chronic Pain Management Unit in the same teaching hospital. Consecutive patients referred on strong 
opioids were approached to take part in the study and all agreed. Referrals to the unit came from all 
over the UK, and from general practice as well as from hospital-based specialties.
The drug addicts included in the study were taken from consecutive cases attending a methadone 
maintenance programme in a major London teaching hospital, serving a local South London 
population. All drug addicts approached to take part in the study agreed. Drug addicts on a methadone 
maintenance programme will clearly continue to use illicit drugs in addition to the prescribed 
methadone.
The following information (see appendices 1-4) was collected;
1. Demographic data and drug use: at entry to the study
• basic medical and personal information
• past psychiatric history
• drug regimen
• use of unprescribed drugs
• HAD score^® (repeated monthly), this has 7 anxiety and 7 depression questions
2. Assessments
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;) Initial questions at entry:
• reasons for taking opioids, using visual analogue scales (V.A.S.) e.g. to relieve pain, 
to calm, to help sleep, to feel good . . .
» fears about opioids - free text
• prompts to take next dose based on opioid withdrawal symptoms scale (S.O.W.S) in 
addition to questions relating to pain and breathlessness (Yes or No answers)
» maximum daily opioid dose in past week
• pain severity; now and average over past week (V.A.S.)
• pain distress; now and average over past week (V.A.S.)
• opioid side-effects (V.A.S) (drowsiness, constipation, nausea, vomiting)
• disturbed sleep (V.A.S.)
ii) Daily diary (for the first week only, completed in evening and refers to that day) 
pain severity (V.A.S.) 
pain distress (V.A.S.) 
opioid side-effects (V.A.S) 
general well-being (V.A.S)
Regular opioid dose 
extra opioid used
effect of medication (V.A.S) - regular and extra 
other drugs used
questions relating to anxiety and emotions
iii) Weekly diary (for up to 2 years in cancer patients, however for first month only in
other groups):
• maximum dose of opioid taken in 24 hour period over this week
• questions as per daily diary
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iv) Follow-up questions (monthly for 3 months and up to 2 years in some cancer 
patients)
• preoccupation with opioids (V.A.S.)
• effect of opioids on mood (V.A.S.)
• questions from Severity of Dependence Scale (S.D.S.)
• prompts for taking next dose; S.O.W.S. questions in addition to pain and
breathlessness questions (Yes/No replies)
• desires regarding opioid dose changes
• reasons for using opioids (V.A.S.)
The Short Opioid Withdrawal Scale (S.O.W.S) is in the appendices (no. I) and the Severity of 
Dependence Scale (S.D.S) appendix 2. This S.D.S. focuses on control over opioid dose and difficulty 
stopping or interrupting use. These were clearly developed for use in a drug addiction population, 
however, in the absence of a scale validated for use in patients initially prescribed opioids for 
analgesia, these have been used in this study.
These data were collected over the following
1. initially at entry into the study
2. daily for 1 week - (questions relating to drug doses, effectiveness, reasons for taking dose,
side-effects)
3. weekly for 4 weeks
4. monthly for 3 months
The questionnaires were completed by the cancer pain patients at out-patient follow-up appointments 
(the daily diary was completed in between). They were mostly out-patients.
The chronic pain patients were recruited to the study between initial interview on referral and the start 
of treatment several months later. This group completed the initial questionnaire at referral and 
returned the remainder by pre-paid post.
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The drug addicts completed the initial questionnaires at the methadone maintenance clinic and the 
remainder during the attendance at the day unit.
Statistical analysis
All opioids were converted to morphine equivalent 24 hour doses using accepted equianalgesic 
conversions. From the daily diary data, means for 24 hour opioid doses, dose efficacy, pain intensity, 
and pain distress were calculated. For each patient group, correlations were calculated between mean 
daily dose, mean dose efficacy, mean pain severity, maximum pain severity, mean pain distress, 
maximum pain distress, HAD anxiety score, HAD depression score, and age, using Pearson’s 
correlations for parametric data and Spearman’s rank correlations for rating scale and HAD data. The 
number of extra opioid doses over the week of the daily diary was obtained, and compared by 
correlation with mean and maximum pain severity and pain distress. The daily opioid dose was 
compared with ratings of symptoms of constipation, nausea and vomiting, sleep disturbance, 
drowsiness, general wellbeing, and pain severity and pain distress by correlation.
The number of patients in each group endorsing each of the listed opioid withdrawal symptoms which 
cued opioid use was grouped using the categories of (1) attributable to withdrawal (craving, sneezing, 
running nose, yawning, sweating, stomach cramps), (2) emotional (irritability, anxiety, restlessness), 
and (3) somatic excluding pain (stiffness, shaking, feeling hot or cold, heart pounding, breathlessness). 
Comparison of individual symptoms and of these three categories was made using yj or Fisher’s exact 
test where cell numbers were small.
Mean severity of dependence SDS scores were computed from the monthly data and since they were 
reasonably normally distributed, those of the cancer patients and chronic pain patients compared using 
t-tests.
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All analyses were carried out using SPSS 6.01 for Windows.
The disc at the back of this thesis contains all the data for the addiction and tolerance studies using 
SPSS 6.01 for windows.
Results
Fourteen cancer patients, 27 chronic non-malignant pain patients and 30 drug abusers completed data. 
They had been using opioids for a mean of 6 months, 2.2 years and 13 years respectively, in median 
daily oral morphine equivalent doses of 1320 mg, 700 mg and 160 mg. Cancer and chronic pain 
patients had mean age of 59 years and 43 years, drug abusers were younger with a mean age of 34 
years.
Size of dose
For cancer patients, the mean daily dose was unrelated to mean pain intensity or distress (r = 0.220 and 
1=0.201, p>0.5), or to mean dose efficacy scores, V.A.S. for dose efficacy (r=0.109, p>0.5). Nor was it 
related to age (r=0.318, p>0.1), or to HAD anxiety or depression scores (r=0.229,1-0,368, botli
p>0.1).
For chronic pain patients, higher mean daily doses were not associated with mean pain severity and 
distress (r=0.106, r=0.273), with mean dose efficacy (i-0.292), nor with anxiety and depression scores 
(r=0.000,1-0.241), nor age (i-0.172).
For methadone maintenance patients, pain questions were irrelevant to their use, but a higher mean 
daily dose was associated with a greater depression score (r=0.601 p<0.005) but not anxiety (i-0.032) 
or with age (r=0.230).
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Mean dose efficacy:
For cancer patients, mean dose efficacy was inversely related to mean ratings of pain severity, 
(r=0.762, p< 0.025) and distress, (r=0.767, p < 0.025), but not to maximum pain severity and distress, 
(r=0.045,1=0.533). In chronic pain patients, mean dose efficacy was unrelated to mean or maximum 
pain severity (r=0.192, r=0.088) or pain distress (r=0.034, r=0.053). No relationships could be found 
between mean or maximum ratings of dose efficacy and any other variable for drug users.
Cues to take a dose of opioid:
Table 1 illustrates the questions asked about reason for taking the next dose of opioid. These questions 
include the short opiate withdrawal scale questions, in addition to some questions related to pain and 
breathlessness, the therapeutic indications for opioids. These prompts were analysed by grouping 
them into withdrawal symptoms (i.e. symptoms highly unlikely to be due to cancer or pain in these 
groups) emotional variables or somatic variables. While some emotional and somatic variables are 
included in the short opiate withdrawal scale, this scale was not designed for pain patients and no 
useful analysis was obtained using the complete score in all 3 groups.
There is a significant difference between the pain groups and the drug addicts (x^= 30, p < 0.0001) 
when symptoms only attributable to v/ithdrawal e.g. craving, sneezing, running nose, are examined as 
prompts to take a dose of opioid. Similarly for emotional variables (anxiety and/or feeling irritable 
and/or feeling restless), there is a significant difference between pain patients and drug addicts (x^ = 
13.2, p <  0.005)
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Table 1
Prompts to take dose
Cancer Chronic
Pain
Meth
M aint
P
N 11 27 21
by clock 11 15 12 7.5 <0.05
pain severity 10 26 4 35.6 <0.0001
pain distress 9 20 6 12.9 <0.005
problems sleeping 2 14 12 4.7
anxiety 1 3 12 14.9 <0.001
feeling restless 0 3 12 17.8 <0.0005
feeling irritable 1 3 11 12.5 <0.005
stiffness 2 8 8 1.4
breathlessness 2 1 2 2.2
stomach cramps 1 2 13 21.4 <0.0001
heart pounding 0 2 3 1.7
craving 0 1 16 33.4 <0.0001
shaking/twitching 0 4 10 9.9 <0.01
feeling hot and cold 0 1 16 35.7 <0.0001
running nose/eyes 0 1 14 29.3 <0.0001
sneezing 0 0 11 24.1 <0.0001
yawning 0 0 15 24.1 <0.0001
Analysis of the somatic variables excluding pain, (stiffness and/or shaking and/or breathlessness and/or 
feeling hot and cold and/or heart pounding), once again shows a difference between pain patients and 
drug addicts (x^= 12.5, p < 0.005).
For cancer patients, almost all took their opioids by the clock i.e. regularly, as prescribed and there was 
no relationship between the tendency also to take according to pain with emotional or other symptom 
cues. The best therapeutic outcome in cancer pain comes from regular opioid use and this is how 
opioids were prescribed for this group. In addition to regular doses prescribed for cancer pain, extra 
opioid can be taken as required for ‘breakthrough’ or uncontrolled pain. The size of this dose is 
calculated for each patient.
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For chronic pain patients there was a very strong association between taking according to emotional 
cues (anxiety and irritability) and taking according to other somatic symptoms (Fisher’s exact test 
p=0.012). Opioid drugs are often taken irregularly in chronic non-malignant pain patients. This is 
expected since an irregular pattern of drug use is the usual before entering the pain management 
programme.
For drug users, there was no relationship between taking opioids and emotional cues, or according to 
other somatic symptoms (other than those classified as ‘withdrawal’ symptoms).
Figures I to X (p29-31) illustrate these findings: red represents cancer patients, green, chronic non- 
malignant pain patients and blue, drug addicts.
Taking extra doses of opioid:
For cancer patients, the number o f extra opioid doses taken over the week was associated weakly with 
mean pain severity (i-0.647, p<0.05) and distress (i-0.697, p<0.05), and more strongly with maximum 
pain severity (r=0.855, p<0.005) and weakly with maximum pain distress (r=0.678, p<0.05).
For chronic pain patients, the number of extra opioid doses was associated with no pain variables 
( i-0 .125 to 1-0.316) for the whole group, but for those scoring below the cutoff point o f 11 on the 
HAD depression scale, that is, whose scores were not of clinical concern, there was a very similar 
pattern to that seen in the cancer patients between the number o f extra opioid doses over the week and 
pain scores: with mean pain severity (r=0.596, p<0.05), with maximum pain severity ( i - 0.774, 
p<0.001), and with maximum pain distress (r=0.581, p<0.05).
For drug users, there was no predictor of using any drugs in addition to the methadone script. Drug 
availability is the crucial factor in the addict group.
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For none of the three groups was taking extra opioid doses over the week associated with anxiety or 
depression, (HAD scale) or taking versus not taking extra opioid doses with initial fears (that is, at the 
start o f taking opioids) about possible addiction or about other issues such as adverse effects.
Symptoms of dependence score: (Appendix II)
The S.D.S. was completed monthly. Good quality S.D.S. data were only obtained from 5 patients with 
cancer pain and 15 chronic non-malignant pain patients. Mean S.D.S. scores were similar across the 
two groups (10.3 (s.d. 2.5), 9.5 (s.d. 2.1) respectively), for both this is a clinically significant score 
from a possible maximum of 15. However, both groups of pain patients scored high on having 
difficulty with the idea of stopping and lower on anxiety and worry about opioid use. There was no 
relationship between these concerns about opioid use and mean daily oral morphine equivalent dose.
Relationship between oral morphine equivalent dose and symptoms:
There was no linear relationship between oral morphine equivalent dose and mean daily scores over 
the first week of constipation, nausea and vomiting, sleep disturbance, general well-being, drowsiness, 
pain severity or pain distress. Even if  the highest opioid doses are excluded along with those rating 
mean constipation less than 1 on a V.A.S. (0-10), there is no relationship between opioid dose and 
constipation.
Chronic non-malignant pain patients were more likely to vary opioid dose; seventy per cent, compared 
to 30% of cancer patients and 19% of drug addicts.
Discussion
In the cancer pain group the size of opioid dose was unrelated to pain severity or distress. The size of opioid dose 
used to control cancer pain is likely to relate to a number of variables relating to the individual and the pain 
syndrome. We know some pains, particularly neuropathic pains require larger opioid doses. '^* These results are
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consistent with the neurophavmacology and neurophysiology of cancer pain and where opioids are used regularly as 
in this patient group.
The chronic pain patients also showed no relationship between opioid dose and pain severity or distress. Once again 
this is expected for the same reasons as mentioned for cancer pain.
With the methadone maintenance group in this study, higher doses of illicit drugs are associated with higher 
depression scores.
The opioid dose efficacy results reflect the beneficial pattern of regular opioid regimens in cancer patients and the 
more chaotic and at times less effective regimens in chronic pain patients. However there was no evidence of 
analgesic tolerance in either pain group. Opioids remained effective if used regularly.
Clearly in drug users the efficacy of drug use will depend on individual factors, e.g. degree of tolerance. There was 
no predictor of opioid use in drug addicts which is most likely due to the fact that drug availability is the 
overwhelming keystone to opioid use in this group.
The pain patients were understandably not keen on stopping opioid use because of the beneficial 
effects on pain; this is an example of how a score developed for drug addicts is not helpful in other 
populations.
Conclusions
Cancer pain and chronic non-malignant pain patients used opioids mainly to relieve pain; drug abusers 
used opioids for mood and sleep.
Chronic pain patients were more depressed than both other groups and took extra doses when pain was 
more distressing; cancer patients took extra opioids when pain was poorly controlled; for drug abusers 
there was no obvious cue for drug use and availability seems the most likely factor.
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These analyses show no evidence of opioid dependence or opioid withdrawal symptoms in the 2 pain 
groups (if somatic symptoms are excluded), using these scales validated for use in drug addicts. 
However, more useful and meaningful data has been obtained by analysis of opioid use, effectiveness 
of opioids, reasons for use, methods of use.
Opioids have predictable pharmacokinetic and pharmacodynamic profiles and are therefore prescribed 
in a regular fashion for chronic cancer pain with the aim of pain control while accepting that at times 
extra doses will be required for ‘breakthrough’ pain. This strategy works for the majority (80%) of 
cancer patients.^^ It is obvious from this data that although some o f the cancer patients in this study 
had difficult pain, requiring very large doses of opioids, all of the cancer pain group used opioids to 
relieve pain and took extra doses when the pain was poorly controlled. The efficacy was predictably 
related to lower levels o f pain severity.
Chronic pain patients traditionally use analgesics in a less structured way than cancer pain patients and 
this is commonly prescribe!' dictated. Chronic pain management with opioids is poorly addressed in 
the U.K. However, it is interesting to note that higher doses coexisted with better pain control and a 
regular regimen was associated with higher drug efficacy. Chronic pain patients otherwise used 
opioids in response to emotional cues such as irritability and anxiety. It is common to find these 
features with uncontrolled chronic pain and they are often misinterpreted in clinical practice. This 
group tended to use extra doses with higher pain severity and pain distress ratings. This is another sign 
of appropriate opioid use in chronic pain.
The drug addict group on higher doses of illicit drugs had more depression and lower maximum rating 
of efficacy, the latter a sign of pharmacological tolerance. This was not evident in the pain groups. 
There was no predictor at all o f when drug addicts would use illicit drugs and the assumption must be 
that unlike the pain groups this is related to availability.
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There are profound differences in use and subjective effects of opioids between pain patients and drug 
abusers. This study goes beyond the inadequate definition of addiction which has been unhelpful by 
itself in the chronic pain situation. The situation of addiction or psychological dependence in the pain 
situation may be further clarified by examination of patients on a regular opioid regimen and good pain 
control over a longer time. This is addressed in the next chapter. The chronic drug-seeking 
behaviour of chronic pain patients who get analgesia from opioids is often misinterpreted. This is 
‘pseudo-addiction’.
The paradoxical position of opioids, and a sensible, acceptable approach to their use could be clarified 
by communication between addiction specialists and physicians managing pain. The former have used 
their observations in addicts to establish a language and understanding of risk factors and outcomes of 
abuse, but have little if any experience of opioid use for pain, the latter have insufficient knowledge of 
the criteria by which drug abuse is defined and strategies o f management of abuse.
Pain relief is a fundamental duty of every physician, however, proactive communication between medical disciplines 
about the use o f opioids is lacking.
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The following reasons for taking opioids showed statistically significant 
Differences between 1) Cancer (red) and Chronic pain (green) patients 
And 2) Drug abusers (blue);
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Initial Questions
Patient Name
Patient No
Today’s Date ...../ ....../
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INITIAL QUESTIONNAIRE (+ demographic data + HAD: supervised completion
1, Opioids have a range of effects. Please indicate on the lines below what effects they have when 
you take them. You can put a mark anywhere along the line, between the left hand end, ‘not at all’, 
and the right hand end, ‘very much so’.
I take opioids to help relieve pain
not at all very much so
1 take opioids to help calm me
not at all very much so
1 take opioids because I feel worse if I don’t
not at all very much so
I take
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DAILY DIARY
Patient Name
Patient No
Today’s Date /.......... /.
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DAILY DIARY (daily first week, self-completion)
1. If you are in pain:
On average how severe was your pain today?
No pain _____ ___ _________________ ____ _ worst pain 
possible
On average how much did your pain distress you today? 
No distress ___________    .
2. How much have you been feeling sick (nauseous) today?
worst distress 
possible
Not at all all the time
3. Have you been constipated today? 
Not at all  ________ severely
4. Has your sleep been disturbed today? 
Not at all . __________ _ very disturbed
5, Have you felt drowsy today?
Not at all 
drowsy
extremely
drowsy
6. How has your appetite been today?
Very poor 
appetite
very good 
appetite
7 How have you been feeling generally today? 
Very u n w ell____________________________ _ very well
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Regular m edication/prescribed medication
8. Total dose to d a y ........................................mg
9. How much effect did you get from your regular medication today? Please mark the line at the point 
which best represents the relief you get from your regular medication.
No effect Maximum effect
Extra Medication
10. Did you take any other opioid today? Yes No
If yes:
Wliat did you ta k e ? .........................................................
What dose did you take?................................................ mg
How often did you take i t ? ...........................................times per day
How much effect did you get from this?
No effect ...................         Maximum effect
11. Did you take any other drug today? Yes No
(other than your regular prescribed drugs)
If yes:
What did you tak e? .............................................................
What dose did you tak e? ................................................... mg
How often did you take i t ?  times per day
12. Did you get any unpleasant side effects from either your regular /prescribed medication or the 
extra medication/ (please ring) Yes No
If yes, please list the side effec ts................................................................................................................
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13. Did anything else affect how much opioid you took today? (please ring) Yes No
If yes, please say briefly what affected how much you to o k ..........................................................
14. Did anything else affect how you felt today? (please ring) Yes No
If yes, please say briefly what it was, and how you f e l t ..................................................................
15. If you are in pain, do you drink alcohol to relieve the pain?
(Please ring) Yes No
If yes, how often do you do s o ? ...........................................times a day
If yes, how much do you d rink? .......................................... in total each day
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DAILY DIARY
Patient Name
Patient No
Today’s Date /.......... /.
38
DAILY DIARY (daily first week, self-completion)
1, If you are in pain:
On average how severe was your pain today?
No pain _____ ____ _____________________ worst pain 
possible
On average how much did your pain distress you today?
No distress _____________ _____________ ________ _____
2. How much have you been feeling sick (nauseous) today?
worst distress 
possible
Not at all all the time
3. Have you been constipated today? 
Not at a l l  _________ _______ severely
4. Has your sleep been disturbed today? 
Not at all ________________________ very disturbed
5. Have you felt drowsy today?
Not at all 
drowsy
extremely
drowsy
6. How has your appetite been today?
Very poor 
appetite
very good 
appetite
7 How have you been feeling generally today? 
Very u n w ell___________ ___ ________________ very well
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Regular m edication/prescribed medication
8. Total dose to d ay ........................................mg
9. How much effect did you get from your regular medication today? Please mark the line at the point 
which best represents the relief you get from your regular medication.
No effect Maximum effect
Extra Medication
10. Did you take any other opioid today? Yes No
If yes;
What did you ta k e ? .........................................................
Wliat dose did you take?................................................ mg
How often did you take i t ? ...........................................times per day
How much effect did you get from this?
No effect ....................................      Maximum effect
11. Did you take any other drug today? Yes No
(other than your regular prescribed drugs)
If yes:
What did you ta k e ? ....................... .....................................
Wliat dose did you ta k e ? ................................................... mg
How often did you take i t ?   ..................... times per day
12. Did you get any unpleasant side effects from either your regular /prescribed medication or the 
extra medication/ (please ring) Yes No
If yes, please list the side effec ts................................................................................................................
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13. Did anything else affect how much opioid you took today? (please ring) Yes No
If yes, please say briefly what affected how much you to o k ..........................................................
14. Did anything else affect how you felt today? (please ring) Yes No
If yes, please say briefly what it was, and how you f e l t ..................................................................
15. If you are in pain, do you drink alcohol to relieve the pain?
(Please ring) Yes No
If yes, how often do you do s o ? .......................................... times a day
If yes, how much do you d rink? ..........................................in total each day
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Weekly Diary
Patient Name
Patient No
Today’s Date /....... /.
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W EEKLY DIARY (weekly throughout the study, self-completion)
1. What is the maximum daily dose this week of your opioid m edication..................mg
Have you made any changes to your opioid medication/opioid use this week?
If so what changes?
2. If you have pain, how severe has your pain been today?
No pain 
possible
worst pain 
possible
3. On average, how severe has your pain been this week?
No pain 
possible
worst pain 
possible
4. If you have pain, how much has it distressed you today?
No distress worst distress 
possible
On average, how much has your pain distressed you this week?
No distress worst distress 
possible
6. How much have you been feeling sick (nauseous) this week?
Not at all all the time
Have you been constipated this week?
Not at all very severely
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8. Has your sleep been disturbed this week?
Not at all  ___ __________ _________ _________________________________ _ very disturbed
9. Have you felt drowsy during the day this week?
Not at all _____________________ ___________ __________ __ _________ __ extremely
drowsy drowsy
10. How has your appetite been this week?
Very poor __________ ___ ________________________________________ _ very good
appetite appetite
11. How have you been feeling generally this week?
Very u n w ell_____________________ ______________________ __________________  very well
R egular m edication/prescribed medication
12. Total dose to d a y ............................................mg
13. How much effect did you get from your regular medication today? Please mark the line
at the point which best represents the relief you get from your regular medication.
No effect ____________________________________________ __________________  maximum effect
E xtra medication
14 Did you take any other opioid today? Yes No
If yes:
Wliat did you ta k e ? ............................................................
What dose did you take?...................................................mg
How often did you take i t ? .............................................. times per day
How much effect did you get from this?
No effect ........................ ......................................... ................. ..........  ............. . ........... Maximum effect
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15 Did you take any other drug today? Yes No
(Other than your regular prescribed drugs)
If yes:
What did you take?................................................................
What dose did you ta k e ........................................................mg
How often did you take it?....................................................times per day
16 Did you get any unpleasant side effects from either your regular/prescribed medication or the extra 
medication? (please ring) Yes No
If yes, please list the side effects
17 Did anything else affect how much opioid you took today? (please ring) Yes
No
If yes, please say briefly what it was, and how you felt
18 Did anything else affect how you felt today/ (please ring) Yes No
If yes, please say briefly what it was, and how you felt
19 If you are in pain, do you drink alcohol to relieve the pain?
(please ring) Yes No
If yes, how often do you do s o ? ............................... times a day
If yes, how much do you d rin k ? .............................. in total each day
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Follow-up Questions
Patient Name
Patient No
Today’s Date /.... /
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FOLLOW -UP QUESTIONNAIRE (monthly at clinic visit or self-completion) 
Please think of your opioid use during the last week when you answer these questions.
1. How much do you think about your opioids during the day?
never all the time
How much do you think the opioids affect your mood?
negative 
effect 
on mood
positive 
effect 
on mood
Please answer each question by circling one response only. 
Over the last week . . .
3. Did you think that your opioid use was out of control?
Never or 
almost never
Sometimes Often Always or 
nearly always
Did the prospect of missing a dose make you very anxious or worried?
Never or 
almost never
Sometimes Often Always or 
nearly always
Did you worry about your opioid use?
Never or Sometimes
almost never
Often Always or 
nearly always
Did you wish you could stop?
Never or 
almost never
Sometimes Often Always or 
nearly always
How difficult would you find it to stop using opioids or to go without opioids?
Impossible Very Quite Not Difficult
difficult difficult
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How do you decide when to take your next dose? Please answer Yes or No to as many 
reasons as apply to you.
By the clock Yes No
Pain intensity - when pain is severe Yes No
Pain distress - when pain distresses you Yes No
Aches in muscles Yes No
Breathlessness Yes No
Feeling anxious Yes No
Feeling restless Yes No
Feeling irritable Yes No
Feeling sick Yes No
Difficulty sleeping Yes No
Feeling stiff Yes No
Heart pounding Yes No
Feeling hot and cold Yes No
Had gooseflesh Yes No
Stomach cramps Yes No
Runny eyes or nose Yes No
Feel craving Yes No
Yawning Yes No
Sneezing Yes No
Sweating Yes No
Twitching/shaking Yes No
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9, W ould you like to change your regular dose o f opioid? (please ring one)
increase decrease
How would this improve things?
no change
10. Opioids have a range of effects. Please indicate on the lines below what effects they have 
when you take them. You can put a mark anywhere along the line, between the left hand 
end, ‘not at all’, and the right hand end, ‘very much so’.
I take opioids to help relieve pain
not at all very much so
I take opioids to help calm me
not at all very much so
I take opioids because I feel worse if 1 don’t
not at all vei-y much so
I take opioids to help my sleep
not at all very much so
I take opioids to make me feel good
not at all very much so
I take opioids to help my breathlessness
not at all very much so
I take opioids to relieve stress
not at all very much so
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s.o.w.s
Appendix I
Name: Date:
Please put a tick in the appropriate box if you have had any of the following during the last 24 hours.
None Mild Moderate Severe
Feeling sick
Stomach cramps
Muscle spasms/twitching
Feelings of coldness
Heart pounding
Muscular tension
Aches and pains
Yawning
Runny eyes
Insomnia/ problems sleeping
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S .D .S
3. Did you think that your opioid use was out of control?
Appendix II
Never or 
almost never
Sometimes Often Always or 
nearly always
4. Did the prospect of missing a dose make you very anxious or worried?
Never or 
almost never
Sometimes Often Always or 
nearly always
5. Did you worry about your opioid use?
Never or 
almost never
Sometimes Often Always or 
nearly always
6. Did you wish you could stop?
Never or 
almost never
Sometimes Often Always or 
nearly always
How difficult would you find it to stop using opioids or to go without opioids?
Impossible Very
difficult
Quite
difficult
Not Difficult
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Chapter 4
Note to examiner: methods section is the same as chapter 2.
Clinical Tolerance to Opioids
Clinical tolerance to opioid analgesia in man results from a complex series of phenomena. Tolerance 
refers to a phenomenon in which exposure to a drug results in the diminution of an effect or the need 
for a higher dose to maintain an effect.' In quantitative terms tolerance is demonstrated by a shift to 
the right of the dose-response curve and an increase in the opioid ED50 value (the dose required to 
produce an effect in 50% of the population).^ ^
Tolerance can be innate i.e. genetically deteimined, or acquired. Acquired tolerance can be 
pharmacokinetic, pharmacodynamic or learned tolerance.
Pharmacokinetic tolerance refers to changes in the distribution or metabolism of the drug after repeated 
drug administrations that result in reduced concentrations in the blood and subsequently at the sites of 
drug action. The most common mechanism is an increase in rate of metabolism of the drug, as in the 
case of barbiturates.
Pharmacodynamic tolerance refers to adaptive changes that have taken place within systems affected 
by the drug, such as drug-induced changes in receptor density and second-messenger systems, so that 
response to a given concentration of the drug is reduced.^
Learned tolerance refers to a reduction in the effects of a drug as a result of compensatory mechanisms 
that are learned. Conditioned tolerance is a type of learned tolerance. It is situation specific and 
develops when environmental cues are consistently paired with the administration of the drug.''
When a drug affects homeostatic balance by producing sedation and changes in blood pressure, heart 
rate and gut motility, there is usually a reflex counteraction or adaptation that attempts to restore the 
status quo. If the drug is always preceded by the same cues, the adaptive response to the drug will be
55
learned and this will prevent the full manifestation of the drugs effect (tolerance). If the drug is taken 
under different circumstances e.g. after a different ritual in the case of the drug addict, tolerance to that 
particular dose is reduced and the drug effect enhanced. This explains why a drug addict may suffer a 
respiratory arrest with a dose of opioid, which had previously resulted in no respiratory depression, if 
the drug is taken under different circumstances. This is a generally accepted phenomenon in A & E 
departments.
It is claimed that patients with pain who receive opioids repeatedly, develop tolerance to the analgesic 
effects.^ Opioid tolerance is manifest when a given dose of an opioid produces a decreased effect or 
when a larger dose is required to maintain the original effect. This tolerance is not due to 
pharmacokinetic changes in the disposition of the opioid but rather it is a pharmacodynamic type of 
tolerance that results from neuroadaptive processes.
The loss of analgesic efficacy as a result of tolerance does not usually limit the clinical use of opioid 
drugs, because the development o f tolerance to the respiratory depressant and other limiting effects 
allows the dose of opioid to be increased through dose titration.
The usual method of assessing the presence or absence of tolerance in the clinical setting is dose 
escalation. Studies using opioid dose escalation show that the rate and extent o f tolerance differ 
dramatically among pain patients.®'^ Unfortunately the yardstick of disease progression causing opioid 
dose escalation can be a very inaccurate measurement. Disease progression leading to an increase in 
pain is not always easily measured even with sensitive investigations. Furthermore, a stable opioid 
dose does not necessarily imply no analgesic tolerance, since pains may resolve either spontaneously or 
with some intervention e.g. radiotherapy or chemotherapy. It is reasonable to say that opioid dose 
escalation is the response to a number o f variables which leave the patient with an increase in the 
subjective sensation of pain. In the situation of uncontrolled pain, the efficacy of an opioid dose at any 
given time is an indication of lack of pharmacological tolerance to the analgesic effect o f the opioid 
dose which the individual takes at that time. The patient and his pain are their own controls in this 
situation, assuming no significant change in background pain. Similarly pharmacological tolerance to
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the hedonistic effects of opioids in drug abusers can be measured at any given time point by asking 
about the hedonistic or euphorigenic effectiveness of a dose.
The side-effects o f opioids in the chronic dosing situation are sedation, dry mouth, constipation and 
nausea and vomiting. These are usually described as initiation effects and are said to be associated 
with subsequent dose increases. Tolerance develops at different rates to each of the opioid effects.
The measurement of tolerance to wanted effects i.e. analgesia as compared to tolerance to unwanted 
effects has not been measured with any precision in man. Interestingly, the analogy in drug addicts, 
tolerance to hedonistic effects as compared to tolerance to respiratory depression, constipation, nausea 
and vomiting has also not been measured.
Despite the limitations of just looking at pain stimulus there have been useful studies of patterns of 
opioid use in patients with pain. They demonstrate that changes in the pain stimulus, usually 
progression o f the tumour in cancer pain patients, is the most common cause o f opioid dose escalation.’ 
In addition, with chronic non-malignant pain, stable doses of opioids can provide relief for years.® 
While clinical studies of opioid use in patients with cancer pain do not raise anxiety over the issue of 
analgesic tolerance, the phenomenon of morphine tolerance in central hypersensitivity states is 
discussed in Chapter 10.
Our study comparing 3 groups using opioids, provides interesting insight into clinical tolerance as well 
as addiction. This was examined by asking critical questions around tolerance. The three groups 
were: patients with cancer pain, patients with chronic non-malignant pain and drug abusers on a 
methadone maintenance programme. Medical and personal data, mood and patterns of drug use were 
compared in the 3 groups.
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Aim:
The aim of this part o f the study was to establish the relationship of opioid dose to analgesic response 
in pain patients and opioid dose to hedonistic effects in drug abusers and also to compare opioid dose 
to unwanted opioid effects: sedation, nausea, vomiting, and constipation, in all 3 groups. In addition, 
the pattern of dose, efficacy of dose, pain and side-effects was followed over time; 3 months for 
chronic non-malignant pain and up to 2 years for patients with cancer pain.
The issue of rate of opioid dose escalation is complex in the pain situation, however, examination of 
the above parameters was expected to give information about patterns of opioid dosage and help in 
some way to evaluate more objectively clinical tolerance. Similarly in the drug addicts on the 
methadone maintenance programme rate of escalation is complicated due to both availability and 
reporting. We know that to achieve the same hedonistic effects over time, drug addicts do have to 
increase their dose.
Methods
Ethical approval for the study was obtained from St Thomas’ Hospital and all included gave written 
informed consent. Thirty patients in each of the 3 patient groups were enrolled in the study. 
Consecutive patients with cancer pain on strong opioids and a prognosis of at least 3 months referred to 
the palliative care team of a large London teaching hospital with an oncology unit, were considered for 
inclusion in the study. Many of these patients by definition had difficult pain syndromes and were 
using large quantities of opioids. The oral morphine equivalent doses in this study group were 
unusually high at the upper end of the distribution and reflected difficult pain treated for years with 
opioids. All patients approached agreed to take part in the study. This was therefore an ideal group in 
whom to study pharmacological tolerance.
The patients with chronic non-malignant pain included in the study were referred to a tertiary Chronic 
Pain Management unit in the same teaching hospital. Consecutive patients referred on strong opioids
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were approached to take part in the study and all agreed. Referrals to the tertiary unit came from all 
over the UK. This group completed the study while awaiting treatment in the pain unit.
The drug abusers included in the study were taken from consecutive cases attending a methadone 
maintenance programme in a major London teaching hospital, serving a local South London 
population. All drug addicts approached to take part in the study agreed. The drug addicts admitted 
use of illicit drugs while on the programme, however their estimate of total amount in 24 hours is 
probably an underestimate.
The following information was collected:
1. Demographic data and drug use:at enti-y to the study
• basic medical and personal information
• past psychiatric history
• drug regimen
• use of unprescribed drugs
• HAD score (repeated monthly), this has 7 anxiety and 7 depression questions
2. Assessments
i) Initial questions at entry:
• reasons for taking opioids, using visual analogue scales (V.A.S.) e.g. to relieve pain, 
to calm, to help sleep, to feel good . . .
• fears about opioids - free text
• prompts to take next dose based on opioid withdrawal symptoms scale (S.O.W.S) in 
addition to questions relating to pain and breathlessness (Yes or No answers)
•  maximum daily opioid dose in past week
• pain severity; now and average over past week (V.A.S.)
59
• pain distress; now and average over past week (V.A.S.)
• opioid side-effects (V.A.S) (drowsiness, constipation, nausea, vomiting)
• disturbed sleep (V.A.S.)
ii) Daily diary (for the first week only); (completed in evening and refers to that day)
pain severity (V.A.S.) 
pain distress (V.A.S.) 
opioid side-effects (V.A.S) 
general well-being (V.A.S)
Regular opioid dose 
extra opioid used
effect o f medication (V.A.S) - regular and extra 
other drugs used
questions relating to anxiety and emotions
iii) Weekly diary (for up to 2 years in cancer patients, however for first month only in 
other groups):
• maximum dose of opioid take in 24 hour period over this week
• questions as per daily diary
iv) Follow-up questions (monthly for 3 months and up to 2 years in some cancer
patients)
• preoccupation with opioids (V.A.S.)
• effect o f opioids on mood (V.A.S.)
• questions from Severity o f Dependence Scale (S.D.S.)
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• prompts for taking next dose; S.O.W.S. questions in addition to pain and
breathlessness questions (Yes/No replies)
•  desires regarding opioid dose changes
• reasons for using opioids (V.A.S.)
Oral morphine equivalent dose was calculated using accepted conversion ratios. Correlation between 
daily morphine equivalent dose and age, ratings of pain, opioid efficacy and mood were calculated by 
Spearman and Pearson correlation coefficients separately for each group.
These data were collected over the following
1. initially at entry into the study
2. daily for 1 week - (questions relating to drug doses, effectiveness, reasons for taking dose, 
side-effects)
3. weekly for 4 weeks
4. monthly for 3 months
The questionnaires were completed by the cancer pain patients who were mostly out-patients during 
review (the daily diary was completed between visits).
The chronic pain patients returned the questionnaires in a pre-paid envelope, following completion of 
initial questionnaires in the Pain Unit.
The drug abusers completed the initial questionnaires at the methadone maintenance clinic and the 
remainder during attendance at the Day Unit.
The statistics package, S.P.S.S. 6.01 for windows was used to analyse the data and plot graphs to give 
a visual impact of: dose, effect o f dose, pain and side-effects of opioids over time. In addition, the 
results from the statistical analysis described in chapter 3 were studied from the point o f tolerance to 
analgesia and tolerance to opioid side-effects.
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Results
Fourteen cancer patients, 27 chronic non-malignant pain patients and 30 drug abusers entered the 
study. They had been using opioids for a mean of 6 months, 2.2 years and 13 years respectively, in 
median daily oral morphine equivalent doses of 1320 mg, 700 mg and 160 mg. Cancer and chronic 
pain patients had mean ages of 59 years and 43 years, drug abusers were younger, mean age, 34 years.
The mean dose efficacy for cancer patients was inversely related to mean ratings of pain severity, (r = 
0.762, p<0.025) and distress, (r = 0.767, p<0.025), but not to maximum pain severity and distress, (r =
0.045, r = 0.533). (Time scale, 3 months to 2 years, mean 6 months).
The mean dose efficacy for chronic non-malignant pain patients was unrelated to mean or maximum 
pain severity (r = 0.192, r = 0.088) or pain distress (r = 0.034, r = 0.053). (Time scale, 3 months).
No relationship could be found between mean or maximum ratings of dose efficacy and any other 
variable for drug users. (Time scale, 3 months).
Clinical tolerance to the side-effects o f opioids in the 3 groups was as follows:
There was no linear relationship between oral morphine equivalent dose and the mean daily scores 
over the first week of the daily diary of constipation, sedation, nausea and vomiting.
Drug abusers without pain had significantly less constipation than drug abusers with pain or both pain 
groups in this study. This raises the unanswered question of the role of pain in gut motility.
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Discussion
In the cancer pain group the efficacy of opioid on pain severity was significant; greater the efficacy, the 
less the pain severity. This is an anticipated desired effect. The patients with chronic non-malignant 
pain also showed significant efficacy if opioid was taken regularly otherwise efficacy was 
unpredictable. A regular opioid regimen is expected to improve analgesic efficacy. There was no 
relationship between opioid dose and efficacy in both pain groups; this would be expected due to the 
complexities o f the pain syndromes. Frequently higher opioid doses are required for neuropathic pain 
syndromes.^
On the other hand drug abusers described less effects i.e. clinical tolerance, with the opioid the higher 
the dose. This describes clinical tolerance to the desired effect of opioids in drug abusers but not in the 
patients with pain.
Clinical tolerance to both the wanted and unwanted effects o f opioids is a fascinating phenomenon 
made up of complex components. In this study there was no evidence of analgesic tolerance in the 
cancer pain patients nor in chronic non-malignant pain patients. The former had remarkably static 
opioid doses, responses to dose and pain control over a period of up to 2 years, (mean, 6 months), the 
maximum period of data collection. The non-malignant pain group had more chaotic use of opioids 
than the cancer pain patients, however the plots show (p77-82) very clearly that this is chaos not 
tolerance. The pain groups had been using opioids for a mean of 6 months and 2.2 years respectively 
at the study entry. In contrast, the drug abuser group had clear evidence of tolerance to the hedonistic 
effects of opioids and had been using them for a mean of 13 years.
The fact that none of the common opioid adverse effects were related to opioid dose is interesting. 
Since there was no opioid dose relationship with side-effects to opioids in any group, this implies the 
development of tolerance to these effects at any given opioid dose for an individual. The side-effects
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of opioids in the chronic dosing situation are accepted as initiation effects and are likely to increase or 
recur with an increase in opioid dose.
Traditionally it has been said that constipation is opioid dose related although we have previously 
described no relationship between opioid dose and constipation". This data once again supports no 
relationship between opioid dose and constipation.
In addition the data also supports the belief that drug addicts do not walk about the streets constipated. 
This group do develop more tolerance to constipation than cancer or chronic pain patients, unless pain 
is also present in the drug addict. The phenomenon of pain and constipation is interesting and may 
relate to obvious factors such as immobility and poor dietary intake or to less obvious factors such as 
tachykinins involved in the soup of neurotransmitters in pain, adversely affecting gut motility
The fact that clinically relevant pharmacological tolerance is generally accepted not to be an issue in 
cancer pain management is backed by this data. Similarly no evidence of tolerance is seen in non- 
malignant pain patients. The plots of opioid use, pain and effects are demonstrated here for 2 cancer 
pain patients and 2 chronic non-malignant pain patients (p 68-76) cases 39 and 41 are cancer patients 
and cases 61 and 62 are chronic non-malignant pain patients. These plots are representative of each of 
these pain groups in the study. The remaining plots are in the disc at the back of this thesis.
Conclusions
There is no evidence of pharmacological tolerance to the analgesic effect of opioids, no matter how 
high the dose required, in the cancer pain patients in this study. Constant doses can be used for long 
periods of time - up to 2 years in one patient in this study. It is similarly interesting to note that in the 
chronic non-malignant pain group, use of opioids can be more chaotic than in cancer pain, however 
there is no evidence of a gradually increasing dose over time and dose/efficacy relationships remain on 
the whole chaotic and unpredictable.
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This is in contrast to the drug addicts who we know to require increasing doses to achieve the same 
effects over time.'* In this study the drug addicts described fewer desired effects the larger the dose, 
reinforcing our knowledge on pharmacological tolerance in this group.
These results clearly also demonstrate that pharmacological tolerance does occur to opioid adverse 
effects.
This is important data from the point o f view of education and practical care o f patients.
Current work is under way to look more precisely at the rate o f development o f tolerance to the opioid 
side-effects o f different opioids.
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Chapter 5
Do patients who have received intravenous opioids post-bone marrow transplant (B.M.T.) develop 
physical dependence?
Physical dependence on opioid analgesics is manifest by withdrawal symptoms if the drug is abruptly 
discontinued or an antagonist is administered. The prevalence of physical dependence associated with the 
therapeutic use o f opioids is not known.
It is well recognised anecdotally that some patients may be able to withdraw therapeutic opioids abruptly, 
even after taking them for long periods of time, whereas others may exhibit clear cut physical symptoms of 
withdrawal. This has been a source of great confusion in the past because physical dependence used to be 
equated with addiction whereas we now regard it as just one component o f addiction, the most important 
component being psychological dependence or drug craving. Clearly the presence of physical dependence 
without psychological dependence can occur in the absence of addiction.
The general belief which has evolved is that patients who have received analgesic doses of opioids for up 
to two weeks may be able to discontinue the drug with only mild symptoms, usually not attributed by either 
patients or physician to withdrawal. It is said that in most instances, the major complaint is slight 
irritability and difficulty in sleeping. This has however never been systematically examined.
In contrast, an individual using opioids primarily for euphoric effects may develop withdrawal symptoms 
as soon as the scheduled time for the next dose has passed.
The characteristics and intensity of withdrawal symptoms vary greatly and may be influenced by a variety 
of factors as the specific drug used: dosage, intervals between dosage, duration of use, and even one’s
83
psychological state. It is helpful to distinguish between those signs and symptoms considered to be 
oriented toward obtaining an opioid drug (purposive) and those that can be objectively evaluated and are 
independent of the environment or psychological state of the patient (nonpurposive).* These phenomena 
have been described in relation to drug addicts and not the patient using opioids for therapeutic reasons.
Purposive phenomena can appear quite early. The earliest symptom is anxiety, usually manifested by 
drug-seeking behaviour, which in the clinical setting takes the form of immediate requests for additional 
analgesia. Purposive behaviour usually reaches peak intensity by 36 to 72 hours following the last 
diamorphine injection. It can be modified greatly not only by the environment but also by the presence of 
a calm sympathetic observer.
Nonpurposive symptoms appear 8 to 12 hours after the last diamorphine injection. The intensity of 
symptoms may be considered mild, moderate, marked or severe (tables II & III). Mild symptoms result 
from early autonomic hyperactivity, which may increase in intensity over the first day and then stabilise as 
the syndrome progresses. During the time, pupillary dilation, loss of appetite, tremor, and the appearance 
o f ‘gooseflesh’ due to piloerecta stimulation will occur. At 16 to 18 hours, if an opioid has not been 
administered, the individual may fall into a restless, tossing sleep for two to three hours called the ‘yen’.
On awakening, approximately 20 hours after the last dose, there is further evidence of withdrawal 
consisting of marked restlessness, deep breathing, fever and insomnia. Hypertension is not inft equent, and 
complaints of chills alternating with flushing and vomiting and diarrhoea may appear in two-thirds of 
people. Severe muscular spasms in the extremities were responsible for the origin of the term ‘kicking the 
h ab if, describing heroin withdrawal. Abdominal cramps and bone pain can occur7
The intensity o f withdrawal varies greatly with the specific opioid, as well as dose administered. In 
general, short acting opioids tend to produce brief intense abstinence syndromes, whereas those drugs that 
are slowly eliminated produce mild withdrawal. With morphine and diamorphine, peak intensity is reached
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at 36 to 48 hours, continuing at a plateau for up to 72 hours and gradually subsiding over the next five to 
ten days.
Methadone withdrawal presents a syndrome that develops much more slowly without ever reaching the 
severity seen with morphine. Symptoms rarely occur before 48 hours after the last dose but can last for 
several weeks.'
While acute withdrawal symptoms usually last only 2-3 days, a low-grade protracted abstinence syndrome 
characterised by generalised mild discomfort, poor sense of well-being, and drug craving is well 
described.^
It has been postulated that individuals with chronic pain who use frequent doses of short-acting opioids on 
a regular basis may become physically dependent and develop intermittent withdrawal phenomena, 
including sympathetic arousal, increased muscular tension and receptor ‘hunger’ between doses of 
medications.^ These intermittent withdrawal phenomena - or on-off phenomena - may act to increase pain 
during periods of receptor hunger. Use of longer acting medications, such as methadone, levorphanol, or 
controlled-release morphine, could theoretically avoid such withdrawal phenomena by providing 
continuous, relatively stable blood levels o f opioids.
While on the one hand if the potential for on-off phenomena is eliminated, physical dependency itself may 
represent an inconvenience, on the other hand, it is associated with very negative feelings in prescriber and 
in patients. Fear of a physical withdrawal syndrome can compromise adequate opioid analgesia in some 
acute settings e.g. intensive care, paediatric intensive care and post-operative analgesia, as well as in 
chronic pain, including cancer pain management.
The prevalence of physical dependence associated with the therapeutic use of opioids is not known. There 
is likely to be a spectrum of physical dependence relating to many variables, however, we wanted to
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examine this phenomenon in a group of patients with severe pain lasting days to weeks, as in some 
intensive care or post-operative pain situations.
Patients who receive a bone marrow transplant (B.M.T.) form a homogenous group with a predictable 
cause and duration of pain. B.M.T. usually follows high dose chemotherapy and radiotherapy and patients 
develop a painful mucositis, most severely affecting the mouth causing painful swallowing. This is 
unavoidable, and can last for one to three weeks. Ninety-five per cent o f patients will require intravenous 
diamorphine (the strong opioid of choice in this situation in the U.K.) for some or all o f this time. 
Classically when the mucositis pain resolves these patients discontinue the opioid abruptly hence making 
an ideal group in whom to study opioid withdrawal symptoms.
Aim:
To establish the presence of any signs and symptoms of withdrawal from strong opioids in patients who 
have received intravenous diamorphine by continuous infusion for the treatment of pain due to 
oropharyngeal mucositis post-B.M.T. In addition pain and functional disability caused by oropharyngeal 
mucositis post-B.M.T was monitored.
Methods:
Ethical approval for the study was obtained from U.B.H.T., Bristol. Patients were recruited from a bone 
marrow transplant unit. Consecutive patients were approached pre-transplant. All consecutive patients 
gave written informed consent (or assent in case of children, in presence of a parent).
There is no scale for opioid withdrawal in patients being treated with these drugs for pain. A shortened 
version of the original 32-item scale developed by Gossop for withdrawal in drug abusers has been 
validated. This 10-item short opiate withdrawal scale (S.O.W.S.) was used in the study (Appendix 1).^
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At the same time each day the patient completed the patient diary under supervision (by M.F). Details of 
previous 24 hour requirement o f I.V. diamorphine, concomitant medication, intercurrent medical problems 
along with pulse, B.P. and temperature recordings, were documented. The patient diary included the 
S.O.W.S. (max score = 40), in addition to a functional swallowing assessment (5 point scale, 0 = normal, 4 
= unable to swallow saliva) and a pain assessment. The pain assessment was a visual analogue scale (VAS) 
in all patients and a 5-point smiling faces scale in children younger than 10 years as a cross-check. 
Surprisingly, children in the study all gave VAS scores which were consistent with the smiling faces scale. 
Patients were asked for pain (worst pain present) at time of assessment. (Appendices 1 & II)
The data collection started on day 3 post-B.M.T. and continued until the fourth day after stopping 
diamorphine. All patients reduced and stopped diamorphine very quickly (within 24 hours) coinciding 
with resolution of mucositis. For those patients not requiring diamorphine, data collection continued for 
two weeks from day 3 post-B.M.T.
Analysis
Results were analysed using analysis of variance to look at relationships between diamorphine dose, pain 
and short opioid withdrawal score. Graphs were plotted for the main variables. (Figures I, II, III P. 93).
Results:
Twelve males and 5 females, aged 4 to 39 years (median, 18 years),completed the study. Three patients 
did not require intravenous diamorphine. The duration on diamorphine ranged from 5 to 19 days, median, 
11 days. The median daily dose of diamorphine was 0.78 mg per kg body weight. There was no 
significant difference between children and adults. The median score of swallowing difficulty was 0.75 
pre-diamorphine, 1.55 during diamorphine and 0 after diamorphine was discontinued. The median visual
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analogue scale scores for pain were 11.25, 37.6 and 2, for the periods pre, during and after diamorphine 
respectively.
The S.O.W.S. median scores were 3.2, 3.25 and 2, pre, during and after diamorphine administration.
There was a statistically significant association between swallowing difficulty and diamorphine dose, 
(P<0.001)also between general pain (V.A.S.) and diamorphine dose (P<0.001). There was no correlation 
between S.O.W.S. (short opiate withdrawal score) and diamorphine dose (P>0.4) or duration of use 
(P>0.5). In addition, there was no significant change in withdrawal score from pre, during and post 
diamorphine phases. The figures I, II, III, and table 1 show the above.
Clinical observations were clearly also important during this study. There were no problems in any patient 
on discontinuing the drug.
Conclusions
In this group of bone marrow transplant patients who predictably suffered from oropharyngeal mucositis 
requiring treatment with intravenous diamorphine, there was no evidence of physical dependence to 
opioids as manifested by no evidence of an opioid withdrawal syndrome. The opioid use was short-term 
(up to 19 days) and total daily doses of intravenous diamorphine ranged between 0.78 and 2.24 mg/kg/day 
(total daily dose).
These results are of practical use in many diverse situations. Short-term opioids in the hospital setting is a 
situation where adequate analgesia is sometimes compromised because of fear of withdrawal symptoms 
which might lead to drug-seeking behaviour.
We have previously assumed that the majority of patients being treated therapeutically with opioids 
become physically dependent. However, none of the patients in the study became physically dependent. 
The S.O.W.S. is likely to be an overestimate in these patients because it includes some physical symptoms 
which may occur post-B.M.T. Therefore the scoring system chosen for monitoring withdrawal symptoms 
is not a factor in these results. The route of opioid administration is highly unlikely to have given such 
results since the intravenous route has been implicated in increasing the likelihood of development of 
physical dependence. Intravenous diamorphine (infusion or bolus) is said to start a downward path to 
addiction - this is not the case in this study. The duration of opioid use is also an unlikely factor; patients 
were on opioids for up to 19 days in this study. The dose may be an issue but unlikely; doses of up to 160 
mg of intravenous diamorphine per day are significant doses.
The regimen of a continuous intravenous opioid infusion rather than bolus injections is again an unlikely 
explanation of lack o f physical dependence.
In summary this data shows no evidence of physical dependence in this patient group and clearly shows 
how intravenous diamorphine can be used successfully and then abruptly discontinued. It is important that 
we look at these phenomena in other patient groups and try to include patients who have been using 
opioids for a longer duration.
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Table 1
Pre
Diam orphine
During
Diam orphine
Post
Diam orphine
Duration (days) 
range 5-19 
median 11
Swallowing 
difficulty (medians)
0.75 1.55 0
VAS (mm) Pain 
(medians)
11.25 37.6 2
S.O.W.S
(medians)
3.2 3.25 2
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Table II
Symptoms of Opioid Withdrawal
Early First 10 hours
Anxiety
Sweating
Rapid short respirations 
Slight rhinorrhea and lacrimation 
Dilated reactive pupils
Late 10 hour to 14 days
Marked lacrimation and rhinorrhea
Tachycardia
Tremor
Yawning
Piloerection
Nausea, vomiting, diarrhoea
Abdominal pain
Fever
Leukocytosis
Elevation o f blood pressure 
Diffuse muscle spasm
Prolonged 10 days to several months
Irritability
Fatigue
Bradycardia
Decrease in body temperature
Persistent urinary catecholamine secretion
Hyposensitivity of respiratory centre to carbon dioxide
Table III
Intensity of Withdrawal Symptoms
Mild Moderate Marked Severe
Anxiety
Lacrimation
Rhinorrhea
Sneezing
Sweating
Yawning
All mild signs 
Loss of appetite 
Pupillary dilation 
Piloerection 
Tremor
All moderate signs 
Fever
Hypertension 
Deep breathing 
Nausea
All marked signs 
Vomiting 
Diarrhoea 
Abdominal pain 
Muscle spasms
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Appendix I
Name: Date:
Please put a tick in the appropriate box if you have had any of the following durins the last 
24 hours.
None Mild Moderate Severe
Feeling sick
Stomach cramps
Muscle spasms/twitching
Feelings of coldness
Heart pounding
Muscular tension
Aches and pains
Yawning
Runny eyes
Insomnia/ problems sleeping
How is your swallowing today? Please tick the appropriate box
Normal
Discomfort on swallowing
Difficulty swallowing soft-diet
Severe difficulty - fluids only
Unable to swallow saliva
How is your pain today? Please put a mark on the line
No pain 
at all
worst pain 
possible
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Abstract
Morphine, constipation and performance status in advanced cancer patients
Fifty patients with advanced cancer completed an observational study of constipation. Bowel function was 
assessed weekly for four weeks using a numerical scale measuring frequency of bowel movement, ease of 
passing stool and consistency of stool. Patients surviving were also assessed at six months. Thirty-five 
patients (70%) were constipated on referral to the palliative care service; o f these, eight were not taking 
opioids. The proportion of constipated patients declined during the initial four weeks to 26%. Multiple 
regression analysis showed a highly significant correlation between persistent constipation at four weeks 
and deteriorating performance status, but no correlation between morphine dose and constipation. The 
relationship between morphine dose and laxative dose was examined specifically but no correlation was 
found. O f 12 patients surviving at six months, 10 were not constipated. O f these four were using oral 
morphine equivalent in daily doses o f 40-5250mg but were not needing laxatives, nor other bowel 
interventions and six were not constipated but were needing a laxative in conjunction with oral morphine 
equivalent in doses of 20-3000mg/day.
Oral moiphine invariably causes constipation when used in repeated dosage to treat cancer pain'. Other 
common unwanted effects such as sedation and nausea and vomiting are worse at the start o f treatment with 
morphine but improve with continued use and often resolve completely^. In contiast it is commonly believed 
and taught that morphine-induced constipation does not get better with repeated adminlstiation. We have 
examined constipation associated with morphine in an observational study of patients with pain due to 
advanced cancer.
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Patients, methods and results
Consecutive patients with advanced cancer referred to the Palliative Care Team who were judged clinically by 
a doctor on the team (MF) to have a prognosis of at least four weeks were included in the study whether or not 
they were receiving morphine. Laxatives were prescribed for all constipated patients or patients starting on 
morphine in accordance with a standard protocol (Appendix I). This involves regular administration of a 
combination of a faecal softener and bowel stimulant, with appropriate dose titration according to response, 
and rectal measures as required. For the purpose of the study, patients were assessed by the same individual 
(MF) on referral, at weekly intervals for four weeks, and, for those surviving, at six months. For the first 4 
weeks of the study the patients were seen daily for general review by a member of the palliative care team. 
Bowel ftmction was assessed using a numerical scale designed specifically for this study, incorporating three 
items; fiequency of bowel movements per week (based on the normal bowel habit (N) for each patient: 
0=2<N, MN±1,2=2>N), ease of passing stool (0=difficult, l=normal, 2=easy) and consistency of stool (0=no 
stool, l=hard, 2=normal, 3=loose). Normal function was defined as a total score of 4 or more, and 
constipation 3 or less. Performance status was measured using the ECOG scale (0 = normal activity, 4 = 
bedbound)^. A detailed record of laxative doses was kept and a note was made of concomitant medication.
Results
Fifty patients completed the study (24 males). They were aged 23 to 84 years and had a variety of primary 
cancers. On referral 35 patients (70%) were constipated; of these, eight were not taking opioid analgesics. 
The proportion of constipated patients declined during the initial four weeks to 26%. Factors contributing to 
persistent constipation in this group were examined at the end of the four week period.
Morphine dose, ECOG score, persistent constipation, and non-persistent constipation were examined in a 
multiple regression analysis. This showed a highly significant correlation between persistent constipation as
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measured by the bowel function scores and deteriorating performance status (Figure I). All patients with 
persistent constipation had poor performance status (ECOG 3 or 4) and only 6% of patients with ECOG scores 
in this range were not constipated at four weeks. A comparison of ECOG scores in the persistent constipation 
group and the non-constipated group at four weeks demonstrated a highly significant difference (p = 0.00001).
There was no correlation between morphine dose and persistent constipation, nor between morphine dose and 
ECOG scores. The dose of laxatives was titrated for each patient according to response (not according to the 
dose of morphine). Patients with persistent constipation received the highest doses. O f the 50 patients, 14 
were not receiving morphine, one was obstiucted and one had an ileostomy and was not receiving laxatives. 
Of the other 34 patients, 30 were receiving laxatives containing danthron (either codanthiamer or 
codanthrusate). Doses of danthron ranged from 50-1200mg/day. There was no correlation between the dose 
of morphine and the dose of danthron (r = 0.234 for the 30 patients receiving danthron; r = 0.238 if the whole 
group of 34 patients is included and an assumption is made that they did not need a danthron-containing 
laxative because they had only mild constipation. None of these four patients was constipated at four weeks).
At the six month follow up there were only 12 surviving patients. Four patients were not constipated, nor 
receiving laxatives in spite of using oral morphine equivalent daily doses of 40-5250mg; six patients were not 
constipated but were needing a laxative in conjunction with oral morphine in doses of 20-3000mg/day; only 
two patients had persistent constipation with morphine in spite of laxatives but of these one had a large pelvic 
tumour, and the other a cauda equina syndrome, sufficient in themselves to cause resistant constipation.
Comment
These data conflict with some long held beliefs about morphine-induced constipation. It seems clear that 
assiduous treatment with laxatives is effective in the majority of patients. There was no correlation between 
morphine dose and laxative dose. Persistent constipation in this patient population is more closely related to 
how ill and disabled the patient is (presumably associated with a poor dietary intake) than to their use of
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morphine. We should be less reluctant to treat constipation aggressively in such patients given the misery 
associated with constipation. The suggestion that morphine-induced constipation is dose-dependent^ is clearly 
not supported by our findings. Our long term data suggest that a proportion of patients may become tolerant 
to the constipating effects o f morphine with repeated administration, and do not require continuing treatment 
with laxatives.
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Figure 1
Relationship between resistant constipation and ECOG performance status in 50 consecutive cancer 
patients referred to a palliative care team (Fallon & Hanks)
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Appendix 1
Protocol for management of constipation
1. All patients commencing opioid analgesia for moderate to severe pain should have a prophylactic 
laxative unless a contraindication exists. Laxative dose should usually be increased when opioid dose 
increases. Use a combination stimulant and softener - condanthrusate or codanthramer.
2. If the patient is already on a laxative which is acceptable, a change is not necessaiy and the dose 
should be increased when commencing or increasing opioids for moderate to severe pain.
3. Laxative dose should be titiated up until constipation is controlled.
4. If patient has persisting constipation on maximum dose of codanthrusate (3 tablets, 4 times a day) or
codanthramer 20 mis q.i.d., then half the dose of laxative and add a small bowel flusher - lactulose 15 
mis 3 times a day and increase as required, if tolerated.
5. If hard stool in rectum give glycerine and bisocodyl suppositories and increase the dose of oral 
laxative.
6. If  soft stool in rectum give 2 bisocodyl suppositories (placed next to rectal mucosa) and increase the 
dose of stimulant laxative.
7. If patient has a spinal cord compression or cauda equina syndrome, give alternate day glycerine and
bisocodyl suppositories and titiate oral laxative as required.
8. Enemata should be used if suppositories fail.
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9. Any patient requiring enemata should be re-evaluated to assess reason for constipation and 
appropriate measures taken. This will invariably include an increase in laxative dose.
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Chapter? (Published Paper) Fallon MT. European Journal of Pain 1999; 
3 (supplement A) p.3-7
Constipation in cancer patients: prevalence, pathogenesis, relationship to opioids and 
cost-related issues.
Abstract
Among patients with advanced cancer, troublesome and persistent constipation is a more common 
symptom than pain. The major causes of constipation in cancer patients are inactivity, treatment with 
opioids, and poor fluid intake and nutrition. Opioids act to both decrease gut motility and decrease 
intestinal secretion and therefore harden the stool. Additional aetiologies of constipation may be related 
to the cancer itself, general debility, concomitant diseases, or medication use. Analysis o f results from 
a prospective, longitudinal follow-up study, has confirmed the high incidence of constipation among 
opioid-treated cancer patients and revealed that even optimal management o f this symptom is only 
modestly successful in reducing constipation. This study also indicated that, in constipated cancer 
patients, bowel care entailed an average of 20 to 70 minutes per week of medical time and 55 to 120 
minutes per week of nursing time, underscoring the high financial cost of this symptom to the health 
care system. According to another study, which involved 50 consecutive cancer patients referred to a 
palliative care unit, the development of resistant constipation was independent of moiphine dose. 
However, this study revealed a highly statistically significant correlation between resistant constipation 
and patient functional status, which highlights the critical and often underestimated role o f immobility 
in the development of constipation.
Introduction
Constipation is one of the most troublesome and persistent symptoms in patients with advanced cancer. 
Constipation can cause abdominal and rectal pain, and exacerbate vomiting and nausea. It is also a 
frequent cause of anorexia. Most cancer patients rank constipation as an even more common source of 
distress than pain. In addition to causing discomfort, constipation affects activities o f daily living, 
nutritional intake, and socialization thus compromising quality of life. Recent exciting research into 
neurotransmitters involved in pain shows how complex constipation mechanisms may be.
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Approximately 45% of hospice patients complain of constipation on admission (St Christophers 
Hospice, 1986). Laxative treatment is necessary in about 87% of patients who are receiving a strong 
opioid analgesic (Sykes, 1997). Even among cancer patients who are not being treated with strong 
opioids, as many as 63% may require a laxative (Sykes, 1997). Moreover, despite our best efforts, 
rectal laxatives will be needed in up to 40% of hospice patients, depending on the population 
(Twycross and Lack, 1986).
After a review of the most common causes and underlying mechanisms of constipation in cancer 
patients, this article will describe the findings of a study that investigated the clinical course and 
pharmacoeconomics of this symptom in opioid-treated cancer patients. The relationship of constipation 
to morphine dose and patient performance status is also discussed.
Causes of Constipation in Cancer Patients
The aetiology of constipation in patients with cancer is multifactorial. The chief culprits include 
immobility, opioid analgesics, inadequate fluid intake and poor nutrition. Other contributing factors 
may be related to the cancer itself, such as hypercalcaemia, obstruction from an intra-abdominal 
tumour, spinal cord compression with loss of rectal sensation, cauda equina syndrome with abolition of 
the anocolonic reflex, and depression. Alternatively, the causes of constipation may reflect the 
presence of concomitant disorders such as hemorrhoids, anal fissure, or endocrine dysfunction. In 
addition to opioids, medications such as antiemetics, drugs with anticholinergic action, aluminium 
salts, or nonsteroidal anti-inflammatory agents may also be implicated. The roles of weakness, 
confusion, and difficulty in reaching the toilet should not be overlooked (Fallon and Hanks, 1994).
Exogenous opioids are well known to constipate, not by relaxing intestinal muscle but by suppressing 
forward peristalsis and raising sphincter pressure. These effects are apparent in both the small and the 
large intestine.
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Animal research has revealed multiple putative transmitter peptides and amines in myenteric neurones. 
Acetylcholine and vasoactive intestinal peptide (VIP) are the principle neurotransmitters involved in 
the control o f peristalsis. Anticholinergic agents will obviously induce constipation, however both 
acetylcholine and VIP neurones are modulated by other agents.
Opioid receptors are present on gut smooth muscle cells and on all levels o f intestinal afferent neurons. 
Gut opioid effects involve both central and peripheral receptors in animals, whereas only a peripheral 
opioid contribution has been confirmed in humans (Sykes, 1997). Moreover, in humans parenterally 
administered morphine has been shown to slow gut transit and reduce stool frequency (Kaufman et al., 
1988). It is generally accepted that opioid receptors in the gut wall can be reached via the systemic 
circulation, as well as via the gut lumen.
Constipation-inducing effects of opioids include an increase in the tone of the ileocecal valve and a 
reduction in the peristaltic component of motility in the small intestine and colon. Opioids impair the 
defaecation reflex by reducing sensitivity to rectal distension and by increasing the tone of the internal 
anal sphincter. Increased electrolyte and water absorption in the small intestine and colon has been 
observed during induced diarrhoea in the experimental setting. Fluid absorption in the gut is dependent 
on electrogenic sodium transport that is mediated by the sodium/potassium-ATPase system. At the 
mucosal surface, the cyclic AMP-dependent system that mediates chloride transport and consequently, 
fluid secretion, is a crucial part of the overall process of fluid absorption and secretion. Evidence from 
experimental animal studies has definitively shown that electrolyte and water transport, which is under 
neuronal control, is affected by opioids (Plonowski et al., 1997; Turvill and Farthing, 1997).
Recent research has helped to elucidate the relationship between cancer-associated pain and 
psychological stress and alterations in bowel habit. Tachykinins and tachykinin receptor expression 
have been implicated in disturbances of gut motility caused by stress and pain. Tachykinins affect the 
intestinal muscle and enteric nerves and cause sensitization or stimulation of primary afferent nerve 
fibers. These actions not uncommonly lead to hypomotility, as has been demonstrated in cases of 
postoperative gut ileus. Central neurokinin, (NK,) receptors are also involved in pain-related shutdown
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of gastrointestinal motility. This is a fascinating area for future research; substance P, neurokinins, and 
other tachykinins have attracted much interest in the examination of the plasticity of the central 
nervous system pain pathways. Perhaps we should also be examining such plasticity mechanisms of 
constipation.
Clinical Course and Pharmacoeconomics of Constipation
A prospective, longitudinal follow-up study has been conducted to examine the clinical course of 
constipation in community-based cancer patients with a life expectancy of at least one month who were 
receiving strong opioids. The study excluded patients with a primary bowel malignancy or a stoma.
Five men and 11 women who met these criteria were enrolled in the study. These 16 patients ranged in 
age from 40 to 78 years (median, 63 years). The primary diagnosis was breast carcinoma in six 
patients, bronchial carcinoma in three patients, and other malignancies in seven patients. The duration 
of opioid use spanned one week to two years, with a median of 38 weeks. At entry Into the study, 14 
patients were already taking laxatives and 10 o f these remained constipated despite laxative treatment.
A critical aspect o f the study was the measurement of the constipation score. This score assesses the 
frequency and severity of constipation by quantitating the number of times the bowels opened in the 
last week, the ease of passing stool, and the consistency of stool passed (Table 1), The median bowel 
status score in this group of patients was 2.5 (range, 1 to 4) out of a possible total score of 7, where a 
score of 3 or less is considered to be significant constipation.
Eastern Cooperative Oncology Group (ECOG) scores were used to evaluate functional status in these 
patients. An ECOG score of 0 represents normal activity, a score of 1 indicates that the patient has 
symptoms but is nearly fully ambulatory, 2 means that the patient is in bed for less than half o f normal 
daytime hours, 3 means that the patient is in bed for more than half of normal daytime hours, and 4 
refers to a complete inability to get out o f bed. In this population ECOG scores for the first four weeks 
o f the study ranged from 0 to 2, with a median o f 1.5. The effect o f constipation on patients’ lives
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ranged from 0 to 3 (median, 1.25), where 0 indicates no effect at all and 3 represents a very significant 
effect. The spectrum of typical symptoms associated with constipation is illustrated in Table 2, which 
shows a scatter of prevalence throughout the first four weeks of the study.
Patients kept daily diaries in which they recorded how much time was spent each week talking with a 
hospital physician, general practitioner, or nurse about bowel care. Analysis o f these diaries revealed 
that the major costs associated with constipation are not the costs of laxatives, suppositories, and 
enemata but rather, the costs o f medical and nursing time and possible hospital and hospice admissions 
as a result o f constipation. Bowel care entailed an average of 20 to 70 minutes per week of medical 
time and 55 to 120 minutes per week of nursing time. Despite best efforts to optimize laxative 
prescription and maximize mobility, one to two study participants still required enemata each week.
The outcome of the study revealed that even optimal management of constipation with careful follow- 
up is only modestly successful. After modification of laxative prescriptions, eight patients reported an 
improvement in constipation and six patients experienced no change. One patient remained constipated 
with no obvious symptoms and took no laxatives and the other patient deceased after two weeks of 
study.
It is evident that some patients develop tolerance to the constipating side-effect o f opioids while others 
remain constipated despite best efforts to reverse this symptom. The relationship between resistant 
constipation and lack of tolerance to this opioid effect is not so clear.
Relationship between constipation, opioid dose, and functional status
We studied 50 consecutive cancer patients referred to the palliative care team in an attempt to 
determine the incidence of persistent constipation despite best efforts and to identify those clinical 
characteristics most strongly associated with resistant constipation (Fallon & Hanks, Chapter 6). The 
study population included 26 women and 24 men ranging in age from 23 to 84 years. All patients with 
constipation and all patients starting on morphine were treated with a faecal softener and a bowel
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stimulant and, when required, with rectal measures. Laxative doses were titrated according to clinical 
response.
Bowel function was assessed at the time o f referral, weekly for four weeks and, in surviving patients, at 
six months using the constipation score described above. Detailed records of laxative doses and 
concomitant medications were kept. Overall, 70% of the total population were constipated at the start 
of the study. Over the course of four weeks, this proportion decreased to 26%. The prevalence of 
constipation according to morphine dose at referral, weeks one to three, and week four is shown in 
Table 3. Multivariate regression analysis failed to detect any correlation between morphine dose and 
resistant constipation, as defined by a constipation score < 3 or constipation requiring regular enemata 
in the absence of an obvious cause such as spinal cord compression. There was also no relationship 
between morphine dose and laxative dose.
In contrast, there was a highly significant correlation between resistant constipation and ECOG 
performance status. As illustrated in Figure 1, the highest incidence of resistant constipation was 
observed among bed-bound patients with the highest ECOG score of 4. This suggests that the more 
mobile the patient, the easier it is to resolve constipation and that, conversely, the less mobile the 
patient, the more resistant the constipation is to treatment.
Conclusions
Persistent constipation may be a source of great distress to cancer patients and their caregivers. In 
addition to the personal cost, it is now recognized that the financial cost o f constipation to the health 
care system is high because this symptom is so time-consuming for medical and nursing staff. It is 
clear that the management of constipation must be multifaceted and that even optimal prescription of 
laxatives is not always the solution. It is o f particular note that the study described here shows poor 
mobility of patients, rather than the magnitude of the opioid dose, as a cause of constipation. The 
indicators are pointing towards the fact that resistant constipation is complex and much more than lack 
of tolerance to this opioid side-effect. In the future, new agents that antagonize tachykinin receptors, 
such as NK, receptors, may emerge as an innovative approach to this challenging problem.
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Constipation is not just multifactorial in aetiology, but may emerge as the complex outcome of 
disturbances at neurotransmitter level as well.
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Table 1
Constipation Score
Total Constipation Score; Maximum Score is 7 (3 or less = constipation)
□  Number of times bowels opened In the last week (0-2)
0 >2 times fewer than normal
1 normal + 1
2 >2 times more than normal
□  Ease o f passing stool (0-2)
0 difficult
1 normal
2 easy
□  Consistency of stool (0-3)
0 no stool
1 hard stool
2 normal stool
3 loose stool
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Table 2
Symptoms of constipation in 16 opioid-treated cancer patients participating in a multicentre, 
prospective, longitudinal follow-up study
N um ber of patients experiencing symptom
Symptom W eek 1 W eek 2 Week 3 W eek 4
Pain passing stool 1 1 0 0
Nausea 3 1 0 0
Anorexia 0 1 2 0
Flatulence 2 0 0 0
Abdominal pain 1 2 0 1
Malaise 1 0 1 1
Haemorrhoids 0 1 2 2
Table 3
Prevalence of constipation according to m orphine dose among 50 consecutive cancer patients 
referred to a palliative care team (Fallon & Hanks)
N um ber of patients constipated
M orphine dose Total num ber of 
patients
Time of referral Weeks 1 to 3 W eek 4
0 14 8 (57%) 5 (36%) 0
< 200 mg/day 26 21 (81%) 19(75%) 9 (35%)
201 to 1200 4 2 (50%) 3 (75%) 2 (50%)
mg/day
> 1200 mg/day 6 4 (67%) 3 (50%) 2 (33%)
All dose levels 50 35 (70%) 30 (60%) 13 (26%)
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Figure 1
Relationship between resistant constipation and ECOG performance status in 50 consecutive cancer 
patients referred to a palliative care team (Fallon & Hanks)
□  not constipated 
■  constipated
ECOG score at week 4
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Chapter 8 (Published Paper) Fallon MT, Welsh J. European Journal of 
Palliative Care. 1996; 3(4): 143-146
The role of ketamine in pain control
Ketamine has been used for 30 years as a dissociative general anaesthetic. Ketamine activates the 
limbic system and depresses the cerebral cortex, producing profound analgesia, slight respiratory 
depression, cardiovascular stimulation and amnesia. The protective reflexes are maintained.
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptors are glutamate 
receptors, glutamate having been long recognised as an important transmitter. It is the main excitatory 
transmitter in the central nervous system (CNS).
There has been intense interest in the role of ketamine as an analgesic in recent years, but its 
mechanism o f action and appropriate use are not fully understood. We need to logically and 
systematically examine our approach to its current use as an analgesic and its future evaluation in 
clinical trials.
Transmission of pain
Glutamate is important in the peripheral nociceptive sensory fibres and in the ascending neurones, 
which convey messages to the thalamus and beyond. Glutamate is, o f course, present in a ‘soup’ of 
neurotransmitters. The balance between these neurotransmitters Is constantly fluctuating, hence their 
dynamic role in pain response and in the plasticity o f the CNS.
In addition to the changes in neurotransmitters, evidence suggests that the roles of receptors evolve 
over time. This applies to opioid and non-opioid receptors. An example of the latter is the initial 
activation of AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors in the 
dorsal horn. It is only after AMPA receptor activation that the NMDA receptors are activated, with the
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consequent conversion of a small to large amplitude response and a corresponding increase in pain 
intensity. This will be discussed later as the ‘wind-up’ phenomenon.
These are just some o f the complexities that occur in the central nervous system, resulting in neural 
plasticity. Pain is dynamic, in terms of process and outcome. The role of NMDA antagonists, such as 
ketamine, in influencing the dynamic modification of the nervous system in response to injury has been 
shown experimentally in animals at spinal cord and cortical levels.
Experimental evidence
Animal models of neuropathic pain have helped us to analyse the basic underlying pathophysiological 
mechanisms in difficult pain syndromes such as neuropathic pain.'’^  Among the phenomena observed 
are spontaneous activity of primary afferent neurones and electrophysiological hyperactivity of the 
dorsal horn and spinothalamic tract, altered regional spinal cord metabolism and other CNS 
abnormalities.^'^ These dorsal horn abnormalities may be the result o f the neuronal hyperactivity 
mediated by NMDA receptors and agonists.®’^  In phantom limb pain, somatosensoiy input of 
sufficient intensity and duration may produce lasting changes in central neural structures and, 
therefore, preamputation (pain) experience has a critical role in the genesis of phantom limb pain 
This is thought to be mediated via NMDA receptors.
Key points
• Animal experimental evidence and clinical evidence suggest that NMDA antagonists such as
ketamine can have a useful analgesic role.
•  The analgesic role of ketamine seems to be linked to an alteration in opioid sensitivity.
• The physiological process of ‘wind-up’ correlates with the clinical features of allodynia, 
hyperalgesia, and prolongation of evoked pain response.
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• Those patients with the above triad are most likely to have an analgesic response. Other 
elements o f pain will not necessarily improve.
• Care should be taken with opioid doses when ketamine is introduced: a decrease in the former 
may be necessaty.
Ischaemia-induced hyperalgesia is abolished by direct intrathecal application of NMDA receptor 
antagonists in small volumes. Work on rats suggests that the action in the spinal cord is local.
In inflammation, NMDA receptor activation induces the enhanced pain state.
Clinical role and experimental knowledge
There is substantial evidence that NMDA receptors are involved in the induction and maintenance of 
the pain response in:
wind-up phenomenon 
peripheral inflammation 
peripheral neuropathy 
peripheral nerve section 
spinal ischaemia 
spinal disinhibition 
peripheral ischaemia 
he clinical correlates are:
any pain syndrome with allodynia, hyperalgesia and prolongation of pain response 
inflammatory pain 
neuropathic pain syndrome 
phantom limb pain 
peripheral vascular disease pain
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An essential part o f the future place of ketamine in analgesia is to analyse our current animal 
experimental knowledge and, with the clinical data accrued so far, to formulate an acceptable strategy 
for its use in pain management. This immediately brings us to the wind-up phenomenon. This is 
mediated by the activation of the NMDA receptor, whereby the C-fibre-induced activity o f dorsal horn 
nociceptive neurones is enhanced and prolonged.
Activation of C-fibres can result in a substantial and prolonged increase in the flexion withdrawal 
reflex in rats. This was the first evidence for the existence of central hypersensitivity in pain states, 
now known to be NMDA receptor-mediated.
The wind-up phenomenon has been demonstrated in animals and humans. The NMDA receptor is 
not believed to mediate the initial acute responses to pain: these are transmitted via the AMPA 
glutamate receptor. This is when the soup of transmitters in a dynamic pain process interacts with 
modifying receptors to cause functional alterations in central transmission processes, resulting in the 
clinical phenomena that accompany wind-up.
When the AMPA receptor continues to be stimulated and conditions are right, co-operation between 
the peptides and glutamate released in response to a painful stimulus allow the NMDA receptor to be 
activated. The NMDA receptor then has a crucial role in the maintenance of prolonged pain states. It 
mediates dramatic increases in the duration and the magnitude of cell responses while the input into the 
spinal cord remains constant.
This phenomenon converts simple touch input into the painful sensation to touch we call allodynia. It 
also means that a painful response to any given painful stimulus is magnified (hyperalgesia) and 
prolonged. While wind-up is a process of C-fibres, the central sensitisation that develops means that 
incoming A-fibre inputs are also amplified.
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All these phenomena are sensitive to NMDA receptor antagonists that have been applied intrathecally 
or systemicallyT
Clinical assessment for ketamine use
Clinically, we can identify the triad of allodynia, hyperalgesia, and prolongation of pain response in a 
variety of pathophysiological processes. Sometimes the complete triad is not present, although some 
elements are obvious. It is important to acknowledge that these phenomena may coexist with other 
pain expressions, as we commonly find in the complex mixed pains in cancer pain.
As with the management o f any symptoms, an accurate clinical assessment is critical to successful 
treatment. NMDA antagonists, such as ketamine, are not the answer to all pains that are difficult to 
control with the standard WHO analgesic gu idelin es .T h is  kind of indiscriminate use would only 
hamper further understanding and evaluation of ketamine and cause patients unacceptable side-effects.
We have sufficient experimental and clinical knowledge to select patients who have a good chance of a 
clinical response to ketamine. Patients in neuropathic, inflammatory, ischaemic and phantom limb 
pain groups and those who have the clinical triad o f allodynia, hyperalgesia and hyperpathia which is 
prolongation of pain response, are most likely to have a favourable analgesic response to ketamine. 
They may achieve relief o f the symptoms mediated via the NMDA receptors but still have pain 
mediated via other pathways.
Side effects of ketamine
Sensory information in the brain is processed via NMDA receptor-mediated transmission. It is 
therefore expected that NMDA antagonists will produce several side-effects. The following have been 
described with anaesthetic and subanaesthetic doses used in analgesia:
• Confusion
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•  Delirium
• Vivid dreams
• Hallucinations
• Feelings of detachment from the body
In our experience the adjective most frequently used by patients is ‘strange’.
Some clinicians routinely administer haloperidol or a benzodiazepine, such as midazolam or 
lorazepam, with ketamine. The rationale for using haloperidol is that it binds to central sigma 
receptors that are thought to mediate the excitatory effects o f ketamine at higher doses.
Overuse of haloperidol or benzodiazepines is likely as several o f the symptoms prompting their use 
could be due to opioid toxicity. Animal experiments and clinical studies have shown that NMDA 
antagonists alter the response to opioids.'®’ Furthermore, benzodiazepines increase the 
bioavailability of ketamine by inhibition of hepatic metabolism. Explanations of potential side-effects 
are important and help to decrease anxiety if these side-effects do occur.
Ketamine and opioids
The main action o f opioids is on receptors at C-fibre terminals: release of multiple transmitters from 
these terminals is affected and this explains why opioids are such good analgesics.
There is substantial animal experimental evidence to show that NMDA antagonists attenuate as well as 
reverse morphine tolerance, This correlates with the clinical phenomenon o f appearance or
reappearance of opioid sensitivity, which can be seen after treatment with ketamine begins. This 
improved response to opioids may lead to increased opioid side-effects if the dose is not adjusted 
appropriately.
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Opioid tolerance - or a shift in the opioid dose-analgesic response curve to the right - is a complex area 
and the role of NMD A receptor activation will remain of great interest to researchers. It is another 
example of the great plasticity of the CNS. Some reports indicate that ketamine binds 
stereospeciftcally to opioid receptors in the brain and spinal cord and that naloxone reverses the effect 
of ketamine. Naloxone might reverse the increase in opioid responsiveness in this situation.
It has been observed that hyperalgesia and morphine tolerance may be related by common neural 
substrates that interact at the level of excitatory amino acid receptor activation and related intracellular 
events^*
Lack of response to opioid analgesics is often associated with neuropathic pain, but this whole area has 
become confused. First, the term ‘opioid poorly responsive’ pain is preferable to describe this lack of 
response.^’ This should be a clinical diagnosis made retrospectively after an adequate trial o f opioids. 
In animal studies, loss or dysfunction of presynaptic opioid receptors can be overcome by increasing 
the dose of opioid.^® In pain, where the NMDA receptor is operating and there is reduced opioid 
sensitivity, this, too, can be overcome by dose escalation.^^ Therefore, relative lack o f opioid response 
is a function of many factors, including unacceptable side-effects o f opioid dose escalation.
Any element of pain responding poorly to opioids that can be addressed is important: there is animal 
evidence for NMDA receptor activation in this type of pain, so it makes sense to look at NMDA 
antagonists.
Clinical Use
In the clinic we are sometimes faced with the situation of inadequate analgesia despite an appropriate 
trial o f opioid analgesia (usually morphine) and use of appropriate adjuvant analgesics. This is 
particularly common in neuropathic and some inflammatory pains associated with malignancy. Such 
situations can be associated with much distress, making any movement, toileting, washing, and even 
communicating very difficult.
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Given the significant in vitro and animal in vivo experimental evidence in addition to numerous case 
reports, for the use of NMDA antagonists in certain pain states a protocol (developed by Marie Fallon 
in Bristol) for the use of ketamine in patients with uncontrolled pain due to malignancy was put in 
place (1993 - 1995). Patients who fulfilled the following criteria were approached to give informed 
consent for a therapeutic trial of analgesic doses of ketamine.
1. Alert, orientated
2. Able to give informed consent
3. Patient had an adequate trial o f opioid analgesia titrated against pain
4. Patient had an adequate tidal o f adjuvant analgesia.
5. Patient not showing any signs of opioid toxicity e.g. hallucinations, vivid dreams
6. Diagnosis of pain syndrome is neuropathic and/or inflammatory and/or ischaemic
7. Clinical features must include two of the following three phenomena:
hyperalgesia 
hyperpath ia 
allodynia
8. Opioid dose is reduced by 25% on day 1 o f ketamine and adjusted accordingly. (For caution).
9. Ketamine is delivered by continuous subcutaneous infusion at a starting dose of
0.1 mg/kg/hour and increasing if necessary by 0.1 mg/kg/day every 24 hours up to a maximum 
of 0.6 mg/kg/day.
10. Clinical response is noted daily in terms of:
i) pain - none, mild, moderate, severe
ii) presence of hyperalgesia
hyperpathia
allodynia
Yes/No
Yes/No
Yes/No
iii) ketamine dose
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iv) opioid dose
v) adverse effects: drowsiness Yes/No
hallucinations Yes/No
vivid dreams Yes/No
mycolonic jerks Yes/No
confusion Yes/No
Table 1 (see overleaf) is a summary of the last seven patients in Bristol in whom ketamine has been 
used. A good response often meant that toileting, bathing and cleansing of skin and wounds became 
possible with associated improvement in overall affect and quality of life.
Interestingly, those patients with a partial response (four out of seven patients) required the same 
amount of opioid, while three out o f seven patients who experienced a substantial beneficial effect 
from ketamine all decreased their opioid dose. The range of decrease was between 2,000 mg and 60 
mg (mean 200 mg) of oral morphine equivalent in 24 hours. It is difficult to say if this is a reflection 
of improved analgesia due to ketamine alone, an increased response to opioids or a combination of 
both.
Dextromethorphan is also used as an antagonist at this site and is used to treat cough in the clinical 
setting.
Conclusion
There is good experimental and clinical evidence for the use of the NMDA antagonist ketamine in 
specific circumstances. Ketamine acts by blocking the wind-up phenomenon that happens at the 
NMDA receptor sites, therefore resetting the pain transmission pathway. Clinically, this is manifest as 
blocking allodynia, hyperalgesia and prolongation of the pain response.
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Where this triad is present, particularly in the presence of neuropathic, inflammatory or vascular 
aetiology, ketamine is strongly indicated if the application of the standard WHO analgesic guidelines 
has already been applied.
Care is required with the opioid dose when ketamine is introduced. Sustained-release opioid 
preparations should be substituted with immediate-release formulas and an opioid dose reduction 
should be considered in patients starting a regimen of ketamine for analgesic purposes. The basis for 
this is the clear pre-clinical evidence of an enhanced morphine response when ketamine is added and 
the clinical experience to date with our protocol which backs up the pre-clinical data.
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Chapter 9
Opioid rotation: Does it have a role? -  (Published Paper) Fallon M T. Palliative Medicine, 1998; 
12: 61-62.
Opioid rotation is the term given to a switch in opioids. The aim is to achieve a better balance between 
analgesia and side-effects. The keystone to the rationale behind opioid rotation is incomplete cross­
tolerance.
Tolerance is the phenomenon whereby the dose of a drug needs to be increased to achieve the same 
effect. It is also described as a shift to the right in the dose response curve. Selective tolerance 
describes stable analgesia accompanied by diminution of side-effects.
Tolerance is a complex phenomenon and there has been some controversy as to how often it occurs 
with systemic opioids in the clinical management of cancer pain'. While tolerance occurs to adverse 
effects o f opioids, clinically relevant tolerance to the analgesic effects is thought to be uncommon.
Cross-tolerance describes the phenomenon of tolerance to one drug resulting in tolerance to another 
drug. Incomplete cross-tolerance may apply to wanted effects e.g. analgesia, and unwanted effects e.g. 
sedation, nausea, vomiting, dry mouth and constipation.
The benefit o f a switch from one opioid to another opioid depends on cross-tolerance to the analgesic 
effects being less than cross-tolerance to the adverse effects.
There is clinical evidence that cross-tolerance occurs; the patient with prior exposure to opioids is less 
susceptible to significant opioid-initiation adverse effects. Incomplete cross-tolerance is evidenced in 
the patient who has a recurrence of the initiation side-effects o f opioids after switching opioids, 
Subclinical or even clinical opioid withdrawal symptoms on switching from one opioid to another 
opioid also reflects incomplete cross-tolerance. At a cellular level the theories of incomplete cross-
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tolerance are complex but include binding to different receptor subtypes and the use of different 
secondary messenger systems by different opioids.
The clinical advantage of opioid rotation lies in the possibility of incomplete cross-tolerance favouring 
analgesia more than adverse effects. The disadvantage is that the clinician cannot know in advance if 
an opioid switch will increase analgesia more than adverse effects. In addition, the equianalgesic dose 
of the alternative opioid chosen may be uncertain: it will depend on the opioids being used, the 
individual patient, a degree of cross-tolerance, as well as the nature o f the pain. The patient in the 
higher dose range is potentially at greater risk of the equianalgesic dose being several-fold different 
than expected.
Evidence that tables of equianalgesic dose conversions differ from the clinical situation in opioid 
rotation comes from clinical observations Methadone has been used in opioid rotation, particularly 
in North America. A further complication o f a methadone switch is the emerging NMDA (N-methyl- 
D-aspartate) antagonist activity.
Consideration of the place o f opioid rotation in the management of cancer pain naturally leads to the 
concept of opioid responsiveness. One of the commonest reasons for switching opioids is poorly 
controlled pain with unacceptable adverse affects from the current opioid. It is believed that opioid 
responsiveness should not be judged on the analgesic response to one opioid and should only be 
assessed after a trial o f at least one alternative opioid.^
To avoid unnecessary complication in the management of cancer pain it is important to examine some 
basic clinical facts. Morphine appears to have no clinically relevant ceiling effect to analgesia; hence 
there is no specific point o f pain relief or inadequate pain relief with morphine but a point when 
adverse effects mean further titration of morphine is not possible. Whether unacceptable adverse 
effects occur before adequate analgesia is achieved depends on patient, drug and pain-related factors. 
The anxious patient who uses morphine as an anxiolytic is likely to reach unacceptable adverse effects
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before adequate analgesia. Similarly the inexpert use of morphine, with inappropriately rapid titration, 
lack of attention to prevention and management of adverse effects and inadequate use o f adjuvant 
analgesics will result in unacceptable adverse effects before adequate analgesia is reached.
Some pains are less responsive to opioids than others. Neuropathic pain is commonly quoted as being 
opioid poorly-responsive. There is substantial animal experimental evidence that neuropathic pain can 
be controlled by opioids. However in the clinical situation large doses are often required and adverse 
effects may become unacceptable before analgesia is reached rather than there being not any 
predetermined absence of opioid-responsiveness. Opioid responsiveness is therefore a continuum 
which depends on several factors'*.
It is o f some concern that several o f the reports in the literature advocating opioid rotation, have done 
so on the basis of pain in the confused, agitated, and evidently opioid-toxic patient. A less complicated 
and more predictable approach would be to:
•  review the clinical situation and pain syndrome
• review adjuvant analgesics
• decrease the opioid dose avoiding sustained release preparations
• deal with the altered sensorium secondary to opioid toxicity; using haloperidol or other drugs
• correct any contributing abnormal biochemistry; opioid toxic patients simply do not drink enough
At present none o f the other strong opioid analgesics has been shown to have advantages which would 
make it preferable to morphine for routine use. However there is evidence that a failure to respond to 
one opioid does not mean failure to respond to all opioids and an opioid switch may allow pain control 
to be achieved without disabling side-effects^
The most frequently used alternative opioids are fentanyl, methadone and phenazocine. Oxycodone 
and hydromorphone will be future alternatives. Methadone is a difficult drug to use for the non­
specialist. Titration can be difficult and equianalgesic conversion can be complex. Fentanyl is an
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interesting drug and more precise information is awaited from clinical trials, however it is not suitable 
in the unstable pain syndrome. Phenazocine is a useful alternative to morphine, particularly if 
dysphoria exists. It is important to remember that some of the alternatives to morphine are much more 
potent than morphine.
An active quest for safe, more efficient analgesia, with a better balance between analgesia and 
unwanted effects is our universal aim. Opioids, o f which morphine is the most commonly used, are the 
mainstay of moderate to severe cancer pain management. Opioid responsiveness is a continuum which 
can be affected by many factors, but inappropriate assessment and prescribing can shift a patient to the 
less responsive end of the continuum. Basic reassessment should be a prerequisite before any thought 
is given to opioid rotation.
Opioid responsiveness should not always be based on one opioid and in some situations an opioid 
switch can result in a better balance between wanted and unwanted effects because of incomplete 
cross-tolerance. Opioid rotation will have a place in the management of a selected group of patients. 
We need to examine the pharmacodynamic effects o f the different opioids in the clinical setting, but at 
present this information is lacking.
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Chapter 10
Attenuation of morphine tolerance by an N-methvl-D-aspartate receptor antagonist
It is traditionally taught that pharmacological tolerance to morphine is not a clinically relevant 
phenomenon in cancer pain management. This has been one of the main themes of this thesis. Studies 
o f opioid use in patients with pain demonstrate that changes in the pain stimulus, associated with 
progression of tumour in cancer pain patients, is the most common cause of dose escalation.' While 
physician concern that the development of analgesic tolerance limits the chronic use o f opioids is not 
validated in clinical studies in cancer pain patients, the phenomenon of a specific type o f opioid 
tolerance is o f practical concern in the care o f a subgroup of patients. This group have the clinical 
correlates of central wind up.
Tolerance is a complex phenomenon made up of many mechanisms. The role o f each mechanism will 
vary in each situation. Some of the clinical endpoints are discussed in the accompanying editorial, 
‘Opioid rotation: does it have a role?’ Chapter 9. However, one mechanism of particular interest in 
morphine tolerance is the N-methyl-D-aspartate (NMDA) mechanism.
Recent studies have demonstrated that the excitatory amino acid (EAA) receptor system is involved in 
morphine tolerance and dependence.^ '' Since the I980’s, EAAs, including glutamate and aspartate, 
have been identified as neurotransmitters in the vertebrate central nervous system (CNS). An 
important aspect o f the NMDA subtype of EAA receptor is that it opens a distinctive membrane 
channel, characterised by voltage-dependent Mg^ "^  blockade and high permeability to calcium ions.® 
Physiological increases in intracellular calcium subsequent to receptor activation can initiate several 
metabolic changes in the cell.®'  ^NMDA antagonists including MK801, LY274614, dextromethorphan, 
and ketamine can attenuate or reverse the development o f tolerance to morphine’s analgesic effects.^' ®
It is interesting that the attenuation of morphine tolerance by LY274614 is dose dependent.^ Also, 
animals tested one week after the discontinuation o f drug treatments (LY274614 plus morphine) 
retained their sensitivity to morphine analgesia whereas control animals (morphine only) remained
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relatively toleran t/ ’ Interestingly the ability of LY274614 to affect the development o f tolerance and 
the subsequent sensitivity of animals to morphine requires co-administration of LY274614 when 
morphine is present and therefore occupying opioid receptors.
In contrast to MK801 or LY274614, ketamine is available for clinical drug use. It is a non-competitive 
NMDA receptor antagonist. Ketamine is structurally related to phencyclidine (PCP) and like other 
PGP-like drugs it has anaesthetic, antinociceptive, psychotomimetic, anticonvulsant, neuroprotective 
and amnesic effects.® Animal studies show ketamine to attenuate morphine tolerance.^
Ketamine used in subanaesthetic doses has analgesic effects in h u m a n s . T h e  main side effect at 
subanaesthetic doses are psychotomimetic effects which are usually dose-related.'® There is animal 
evidence to suggest that NMDA receptors are required for both the induction and maintenance of 
morphine tolerance."* The same animal work is consistent with induction and maintenance of tolerance 
involving a time lag consistent with cellular biosynthetic processes.
Central sensitisation of the spinal cord projection neurones may be modulated by the release of EAA’s, 
especially glutamate, and the subsequent activation of the NMDA receptor. These neuronal changes 
may be attenuated experimentally with NMDA receptor antagonists."*
Interestingly the development of tolerance to morphine’s analgesic effects can also be attenuated by 
co-administration of nitric oxide synthesis (NOS) inhibitors.'® The NOS inhibitors, just like the 
NMDA receptor antagonists, can reverse morphine tolerance.'®
Studies to investigate the relationship between NMDA - mediated events and opioid receptor events 
have linked mu receptor occupancy by morphine to protein kinase C activation of NMDA receptors, 
which results in a Ca"^  ^ influx and the formation of nitric oxide. These changes can then result in 
longer lasting changes of gene expression that are the basis of persistent tolerance and dependence.'^ 
Recent work in mice has shown that the both competitive and non-competitive NMDA receptor 
antagonists block the development o f anti-nociceptive tolerance to morphine, but not of that to fentanyl
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nor to a delta selective agonist.’’ This would suggest that there may be significant mechanistic 
differences between the development of tolerance to morphine (with affinity at mu, delta and kappa 
receptors) and more selective mu agonists. This would mean that inhibition of the development of 
opioid tolerance by NMDA antagonists does not happen with all opioids, but is selective for tolerance 
induced by morphine. The other interesting phenomenon is the effect of duration of pain on tolerance 
to morphine. This relates to gene induction, the changing soup of neurotransmitters and plasticity of 
the central nervous system.
Ketamine is widely used to control nociceptive pain in Intensive care and emergency settings.'®’ 
Ketamine has also been used in the management o f patients with cancer related and non-malignant 
chronic pain syndromes.®" However the work reported to date consists of small numbers of case 
reports or more recently small randomised controlled trials in non-malignant pain.®' This work 
attempts to clarify the role of ketamine. All animal experimental work in this area clearly demonstrates 
that it is a combination of morphine plus an NMDA antagonist which is optimally effective in 
preference to an NMDA antagonist alone. We have adopted this approach in our patients. While 
central sensitisation and wind-up are distinct phenomena, both respond to NMDA and the clinical 
correlates of allodynia, hyperalgesia and hyperpathia have been the keystone of our assessment tools.®®
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Aim
The aim of this study was to establish the safety and efficacy of ketamine in a cohort o f patients with 
pain of malignant origin and physical signs of wind-up, which had not responded to morphine along 
with use of appropriate adjuvant analgesics.
M ethods
Consecutive patients referred for management of malignant pain were considered for this study which 
was discussed with the Local Ethics Committee. The unlicensed use of ketamine as an analgesic in 
uncontrolled pain with no other reasonable pharmacological options was considered appropriate.
All patients considered for ketamine infusion had to be alert and orientated and able to give informed 
consent. Patients were eligible for treatment with ketamine if they had received a trial of opioid 
analgesia and adverse effects had limited further titration. A few patients could only tolerate a weak 
opioid such as codeine or dextropropoxyphene but since their action is also through the mu receptor, 
these patients were also included. In addition, each patient had a trial o f an appropriate adjuvant 
analgesic(s). Critical hypertension and/or confusion were the main exclusion criteria. All patients had 
advanced cancer, however only 7 of the 30 patients were in the terminal phase of their illness, i.e. in 
the last weeks of life.
All patients included had to have two out o f three symptoms of; allodynia, hyperpathia or hyperalgesia, 
in addition to a demonstrated lack of analgesia with morphine.
Any patient who had even subtle signs of opioid toxicity e.g. vivid dreams, had a 25 per cent morphine 
dose reduction. All patients were converted to quick-acting morphine preparations, given every 4 
hours, and as required. Controlled-release preparations were discontinued in case of a sudden increase 
in opioid responsiveness leading to opioid toxicity.
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Adjuvant analgesics were not altered during the period of treatment with ketamine.
Haloperidol, 1.5mg orally (repeated as necessary) was made available for any patient who experienced 
any side effects to ketamine. The commonest side-effects at these subanaesthetic doses are 
disassociation from the environment and emotional lability. The majority of the patients, (22), were 
inpatients and 8 were treated as out-patients in the day ward area with careful monitoring. All patients 
had baseline blood pressure recorded and then 4-hourly measurements. Twenty patients had 
subcutaneous infusion (0.1-0.6 mg/kg/hr) o f ketamine and ten had intravenous infusion. Intravenous 
infusion was used for convenience in some patients, particularly out-patients. Both routes are accepted 
practice. The latter had hourly blood pressure recordings and had the infusion of 30 mg o f ketamine 
over 3 hours. The group receiving intravenous ketamine were all out-patients. All patients had an 
average pain score over the past 24 hours and pre ketamine and 24 hours post-ketamine pain scores 
documented.
A recent systematic review by McQuay and colleagues suggest that ‘moderate’ pain is equivalent to 
pain over 35 mm on a 100 mm visual analogue scale and severe pain is equivalent to more than 56 mm 
on a visual analogue scale. In this study responses were noted as none, mild, moderate or severe pain. 
A positive analgesic response to ketamine was considered if a patient had a two step improvement e.g. 
severe to mild pain or moderate to no pain.
Results
Thirty patients with pain of malignant origin received ketamine, 18 females and 12 males, aged 16 to 
74 years. Nine had sarcoma, 4 cervical carcinoma, and the others a variety of other tumours. Twenty 
patients had a continuous subcutaneous infusion, dose range, 0.1 to 0.6 mg/kg/hr, (median 300 mg S.C. 
per 24 hours) and 10 patients had an intravenous infusion, range 30-60 mg (median 35 mg) over 3 
hours.
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Twenty-one patients had a positive analgesic response to ketamine and 9 patients had no response or 
no significant response. Five patients who had a response had a reduction in opioid dose.
Four patients had ketamine related psychotomimetic side-effects requiring haloperidol. One man 
requested the ketamine subcutaneous infusion to be discontinued despite excellent analgesia because of 
emotional lability. There were no serious side-effects.
Figure 1 illustrates the pain levels before and after ketamine and opioid doses before and after 
ketamine. The duration of treatment required seems to vary greatly between individuals and ranged 
from a total o f one infusion, either intravenous or subcutaneous, to a weekly infusion over 5 months.
Patients lived from 4 days to 18 months following treatment (mean 5 months). All patients who 
responded to ketamine appeared to regain responsiveness to opioids, i.e. opioid analgesia was reported 
as more effective than before ketamine.
Discussion
The improvement in pain sought was large in order to compensate a little for any improvement due to 
increased medical input and the placebo effect o f any drug. While a double blind randomised placebo 
controlled trial would be a more robust evaluation of the efficacy of ketamine, the observations in this 
study are nonetheless noteworthy. It seems that an analgesic response, noted in just over two-thirds of 
patients is associated with improved opioid-responsiveness as reported by patients. From in-vitro and 
animal work this would be predicted i.e. the NMDA antagonist renews opioid responsiveness by 
reversing morphine tolerance. Patient selection is important; patients with the clinical correlates of 
wind-up are an obvious choice. We are running a double blind randomised placebo-controlled trial in 
patients with pain due to peripheral vascular disease (same NMDA mechanism involved) and 
neuropathic pain due to malignancy. All patients have access to the active drug if there is no analgesic 
response within 24 hours of receiving the trial drug. However, collaboration with the pharmaceutical 
industry to do a double-blind randomised controlled trial with racemic ketamine and single enantiomer
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S-ketamine is currently underway. This may have the advantage of producing an oral preparation 
without psychotomimetic side-effects.
Conclusion
The NMDA antagonists may be crucial analgesics for future development.
Sadly our ability to control cancer pain with opioids and appropriate standard adjuvant drugs is not 
successful in all cases. At least 50 per cent o f all cancer pain of moderate or severe intensity is 
neuropathic in nature. The clinical difficulty with neuropathic pain is that in many cases the doses of 
opioids required are incompatible with any acceptable side-effect profile.
We have seen the preclinical evidence for morphine tolerance at spinal cord level due to stimulation of 
the NMDA receptor. In animals this can be reversed by NMDA antagonists.
In clinical research trying to tease out morphine tolerance is not easy. Some may argue, what is the 
difference between morphine or opioid unresponsiveness and morphine or opioid tolerance. The 
answer in clinical practice clearly lies with the patients history and like the assessment of opioid 
tolerance has to be a retrospective diagnosis. In the case of this study the diagnosis o f opioid tolerance 
is given by a renewed response to opioid analgesia, which in this study must be due to ketamine since 
no other changes in the patients’ regimens were made.
The clinical histoiy of renewed response to opioid analgesia is straightforward and was volunteered by 
the majority of patients who had improved analgesia following ketamine.
The conclusion I have came to is that as in animal studies, the clinical situation with the NMDA 
antagonist, ketamine, is as a mediator of renewed opioid responsiveness at spinal cord level.
Ketamine reverses central wind-up and hence the clinical correlates, which seem to be poorly 
responsive to opioids alone. These clinical correlates responded well in two-thirds of patients in this 
study to ketamine plus opioids.
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Clearly the future of NMDA antagonists for all appropriate clinical situations depends on current 
clinical trials and availability of a more refined NMDA preparation; the oral route is always preferred 
and failure to produce an oral preparation will bias patient selection. In addition, racaemic ketamine, 
as used in this study can be associated with unacceptable side-effects. However, this area of NMDA 
antagonists role in neuropathic pain and central wind-up associated opioid tolerance, is a very 
important area for future improved analgesia.
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Chapter 11
Difficulties with research in the area of palliative care
There is a view that scientifically rigorous clinical research is incompatible with the basic tenets of palliative care and 
the emotive area of experimenting on the dying has been an ever-present deterrent to some. In palliative care the 
tension between the best possible total care of the whole person and the “greatest happiness o f the greatest number” is 
accentuated. The tension between maximal individual patient comfort and our obligation to gain scientific knowledge 
and improve the care o f future patients is a tangible problem in palliative care research. However, medical progress, 
inclusive of palliative care progress, has to be based on research. Palliative care is a clinical discipline, therefore this 
has to be based on clinical research. Clearly I have approached these clinical studies with the clear intention of not 
compromising best possible care in any way.
Apart from the moral and ethical difficulties which have to be assessed carefully and are clearly far from 
uncomplicated, there are the enormous practical difficulties of doing research with a patient group who have multiple 
problems which are constantly changing and/or evolving. In addition, there is the obvious problem of high attrition in 
all palliative care studies and the problem of easy fatigue in those who remain, making any study with heavy patient 
demands inappropriate.
The practical difficulties in study analysis in this patient group are substantial. The problems include: missing data, 
poor quality data, changing variables within and between individuals over time. New problems will arise 
unpredictably, in addition to patients being lost to follow-up or patients dying. Interpretation o f the meaning of clinical 
data in patients with advanced cancer cannot be divorced from sensible analysis o f data; these two elements must go 
hand in hand to an even greater degree compared to patient populations where there are minimal changes apart from in 
the particular variables under investigation.
It can be very difficult to measure accurately the specific variables under study. This is because palliative care is 
largely concerned with symptom control -  both physical and non-physical -  and most symptoms are ultimately
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subjective sensations e.g., pain, nausea, breathlessness, fear and many others. The quest to find reliable measures for 
palliative care is fraught with difficulties. Ultimately each patient has to be his own control.
This thesis
The studies in this thesis all use validated tools, however, the time required to explain these tools to patients is 
significant and requires revision at each reassessment.
The statistical analysis takes into account missing data and changing variables, in addition to attrition. Hence the use 
of graphs, several statistical tests, depending on parametric or non-parametric data and quantity o f data. Such single 
centre small number studies as described in this thesis clearly lack statistical power in many aspects, however the 
descriptive data obtained along with those data which are robust in statistical power, form a fundamental research 
keystone in this difficult area.
The amount of time and expertise required to gather meaningful data in any palliative care study are overwhelming 
factors. The missing data and attrition in the studies in this thesis are minimal because all patients were personally 
recruited and followed by the one researcher (Marie Fallon).
In the studies reported, I interviewed all the cancer patients personally and did all follow-up. This minimised missing 
data. Unless the researcher is experienced in talking to patients with advanced cancer and understanding their 
difficulties, it is impossible to convey meaningfully how to complete even the simplest o f tools. In addition, subtle 
changes in symptoms and drugs may be missed by the inexperienced interviewer. The data output is closely related to 
researcher understanding of this patient population. This is clearly quite a different scenario from laboratoiy based 
studies or from clinical studies where there are fewer evolving problems and only a small number of easily measurable 
variables of interest. It is clear why descriptive data has such a key role in most palliative care research. In this thesis 
there is a substantial amount of descriptive data, especially in chapters 3 and 4.
The rigorous examination of an area fraught with clinical changes and difficulties is clearly not easy, however there has 
to be the start of such an attempt. This will hopefully allow a greater understanding of the difficulties of research in 
the area of palliative care and enable others to move this agenda forward in a sensitive and appropriate fashion.
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Chapter 12
How does this thesis help to confront opiophobia: Fear of addiction, physical dependence and tolerance?
How does this thesis help to confront these barriers to cancer pain relief? When used correctly, analgesic drug therapy 
is capable of relieving pain in more than 90% of cancer patients.' In reality, patients worldwide continue to endure 
pain. There is one main reason: irrational fears about using opioid analgesics. Fear of addiction is fed by outdated 
knowledge about opioids and the unintended effects o f the war on drugs. Consequently, many health care workers as 
well as patients believe that there is a significant risk of addiction when using opioids for cancer pain.
Fear of addiction among physicians, nurses, and patients has been reported in many places in the world including in 
North America, Asia, Australia and Europe.^ ' '
The irony is that while health care professionals intend to protect patients horn pain, their concerns about addiction, 
which are unfounded, sometimes interfere with pain management. Patients suffer the consequences.
Inappropriate fear o f addiction can be linked to several factors, including legitimate efforts to prevent drug abuse, 
which typically disregard the important medical use of opioids, the media’s preoccupation with only the risks o f drug 
use, widespread confusion about the meaning o f “addiction”, and health care workers’ lack o f knowledge about opioid 
pharmacology.
Confusion between addiction, physical dependence and tolerance
A serious error commonly made by health professionals and the public alike is to use “addiction” to describe physical 
dependence or tolerance. Addiction is defined only by psychological dependence, i.e., compulsive use of a drug for its 
mood-altering properties, and continued use despite harm. Physical dependence is a normal physiological 
consequence o f chronic opioid therapy. Tolerance means decreased effects with a stable dose o f a drug.
Unfoitunately, some medical and nursing textbooks,'^ as well as narcotic control laws'^ have defined addiction as 
physical dependence, thus mistakenly associating addiction with pain management.
149
Despite significant advances in knowledge about the use o f opioids for pain, many healthcare professionals prescribe, 
dispense, or administer opioids inadequately. There is also a misconception among patients, the public and some 
healthcare providers that opioids are “bad” drugs because they are often if not always associated with drug addiction 
and criminal activity. However, studies have shown that opioids used appropriately for pain management are effective, 
safe, and have an extremely low potential to produce addiction.
The safety o f opioids’ long-term use has been well documented.''’ Opioids are remarkably safe compared to many 
other medications. The most prevalent and potentially serious side effect of long-term opioid use is constipation. On 
the other hand, chronic use of non-opioid analgesics can cause stomach, kidney and liver damage. Patients fearing 
addiction must be reassured that opioids are safe.
Improving relief o f cancer pain in the world will depend in part o f eliminating iiTational fears o f addiction to opioid 
analgesics. Health professionals should be the first to overcome their fears, so they can educate patients and families, 
as well as regulators and policy makers. Information about opioids and the true nature o f addiction should become part 
o f health professional education to undo the confusion and misinformation which have made fear o f addiction the 
number one impediment to the medical use of opioids, according to a recent survey of governments.'^
The aims o f this thesis were to clarify beliefs in clinical practice about opioid dependence, both physical and 
psychological, and opioid tolerance. These important and highly topical areas in cancer pain control required clinical 
research which consisted of a series o f inter-related studies.
The process o f carrying out these studies was slow and labour Intensive, however I feel the data collected is o f high 
quality and attrition and missing data very low because o f one researcher. There was no attrition in the bone marrow 
transplant study, constipation study or ketamine study. Attrition in the psychological dependence and tolerance study 
was limited to the cancer pain group in the first week because o f acute deterioration and death, however all patients 
who survived the acute symptom period completed the study. While this is not an easy area o f research, it is clear that 
it is possible to cany out clinical research in the area of palliative care.
The major study in the thesis is covered in chapters 3 and 4. The first hypothesis was ‘Patients with pain and who use 
opioid analgesia do not become addicted to opioids’. This had to be investigated using some lateral thinking to try to
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tease out any features in pain patients which may be similar to drug addict behaviour. There were difficulties with the 
use o f standard tools which have been developed for the drug addict population, however the use o f sensible, clinically- 
relevant questions redressed this problem. What was clear was that cancer pain patients and chronic non-malignant 
pain patients both use opioids to relieve pain and are reluctant to stop because of the beneficial analgesia obtained. 
However, drug addicts use opioids for mood and sleep and are reluctant to stop because o f fear o f a physical 
withdrawal syndrome and need to maintain hedonistic effects.
This information is an important start in the process of dispelling myths about opioid use for analgesia leading to 
psychological dependence. There have been anecdotal reports of safe use of opioids in chronic pain groups, however, 
no study has examined the issues of psychological dependence on opioids in such a systematic fashion in chronic pain 
groups and dmg addicts at the same time. This study has formed the basis o f a much larger study in cancer pain and 
chronic non-malignant pain patients which also includes the collection of qualitative data as well as the use of the tools 
described in the initial study. The examination of opioid side-effects versus wanted effects was the basis o f chapter 4. 
The hypothesis was that patients with pain could use the same opioid dose over time and maintain the same degree of 
analgesia. It is important to show that clinically relevant pharmacological tolerance is not an issue in chronic pain, 
especially cancer pain management; many patients with cancer pain firmly believe that as their disease progresses and 
their pain worsens, the analgesic effect of their opioid lessens and they therefore believe that they will die in pain.
While our clinical experience tells us that analgesic tolerance is not a clinical issue in cancer pain management, clearly 
a stronger evidence base is required for such an important question. This study examines opioid use very carefully in 
the 3 study groups and we see that the pain patients can remain on the same dose of opioid over months, even years, 
with the same amount of analgesia. On the other hand the drug addicts had to use more opioid to achieve the same 
level of hedonistic effects. This begins to give firmer evidence for the clinical belief that clinically'relevant 
phaiTnacological tolerance is not an issue in cancer pain management.
The veiy process of researching the feared issues of addiction and tolerance to opioid analgesia when used for chronic 
pain, especially cancer pain, is in itself crucial. This is the beginning of a process of highlighting an important area and 
starting to tease out some answers to complex questions. As with the psychological dependence study, a larger 
tolerance study with more patients is currently underway.
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The next hypothesis examined in this thesis was to investigate the relationship between opioids and tolerance to their 
side -effects. We see clearly that the over-whelming association between the common opioid side-effect, constipation, 
and opioid dose is far from clear and that persistent constipation despite optimal management is strongly associated 
with poor functional status. This approaches a different aspect o f tolerance, is a unique study and is clinically very 
important. The results o f this study are already being put to good clinical use and it has been chosen by the 
Dannemiller Memorial Educational Foundation as their pain paper of the month.
The thesis then moves on from clinically relevant tolerance, to the examination of morphine tolerance at cellular level 
in a particular subgroup of neuropathic pain. This is a philosophical link between the larger phenomenon of opioid 
tolerance and a more specific mechanistic aspect to opioid tolerance in a small subgroup. The hypothesis for this 
section of the thesis is that overactivation of the NMDA receptor triggers the clinical phenomena of allodynia, 
hyperalgesia and hyperpathia, and that this can be reversed by using the NMDA antagonist, ketamine. In addition, 
overactivation o f the NMDA receptor can be associated with opioid tolerance and reversal o f this or a renewed 
response to an opioid can be induced by using ketamine. Both parts o f this hypothesis did respond to the NMDA 
antagonist, ketamine. This is crucial clinical research from the point o f view o f improving cancer pain which does not 
respond to standard management. Many specialists are already using this information in difficult clinical situations, 
however I have currently the extreme good fortune to develop my ketamine work further in the form of examining S- 
ketamine, ketamine and placebo in a double-blind randomised controlled trial. Therefore this work in addition to the 
other work in the thesis continues to progress.
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